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A B S T R A C T
Background
Familial hypercholesterolemia is one of the most common inherited metabolic diseases and is an autosomal dominant disorder meaning
heterozygotes, or carriers, are affected.Thosewho are homozygous have severe disease. The averageworldwide prevalence of heterozygous
familial hypercholesterolemia is at least 1 in 500, although recent genetic epidemiological data from Denmark and next generation
sequencing data suggest the frequency may be closer to 1 in 250. Diagnosis of familial hypercholesterolemia in children is based on
elevated total cholesterol and low-density lipoprotein cholesterol levels or DNA-based analysis, or both. Coronary atherosclerosis has
been detected in men with heterozygous familial hypercholesterolemia as young as 17 years old and in women with heterozygous
familial hypercholesterolemia at 25 years old. Since the clinical complications of atherosclerosis occur prematurely, especially in men,
lifelong treatment, started in childhood, is needed to reduce the risk of cardiovascular disease. In children with the disease, diet was the
cornerstone of treatment but the addition of lipid-lowering medications has resulted in a significant improvement in treatment. Anion
exchange resins, such as cholestyramine and colestipol, were found to be effective, but they are poorly tolerated. Since the 1990s studies
carried out on children aged 6 to 17 years with heterozygous familial hypercholesterolemia have demonstrated significant reductions
in their serum total and low-density lipoprotein cholesterol levels. While statins seem to be safe and well-tolerated in children, their
long-term safety in this age group is not firmly established. This is an update of a previously published version of this Cochane Review.
Objectives
To assess the effectiveness and safety of statins in children with heterozygous familial hypercholesterolemia.
Search methods
Relevant studies were identified from the Group’s Inborn Errors and Metabolism Trials Register and Medline.
Date of most recent search: 20 February 2017.
Selection criteria
Randomized and controlled clinical studies including participants up to 18 years old, comparing a statin to placebo or to diet alone.
1Statins for children with familial hypercholesterolemia (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Data collection and analysis
Two authors independently assessed studies for inclusion and extracted data.
Main results
We found 26 potentially eligible studies, of which we included nine randomized placebo-controlled studies (1177 participants). In
general, the intervention and follow-up time was short (median 24 weeks; range from six weeks to two years). Statins reduced the
mean low-density lipoprotein cholesterol concentration at all time points (moderate quality evidence). Serum aspartate and alanine
aminotransferase, as well as creatinine kinase concentrations, did not differ between treated and placebo groups at any time point (low
quality evidence). The risks of myopathy (low quality evidence) and clinical adverse events (moderate quality evidence) were very low
and also similar in both groups. In one study simvastatin was shown to improve flow-mediated dilatation of the brachial artery (low
quality evidence), and in another study treatment with pravastatin for two years induced a significant regression in carotid intima media
thickness (low quality evidence).
Authors’ conclusions
Statin treatment is an effective lipid-lowering therapy in children with familial hypercholesterolemia. No significant safety issues were
identified. Statin treatment seems to be safe in the short term, but long-term safety remains unknown. Children treated with statins
should be carefully monitored and followed up by their pediatricians and their care transferred to an adult lipidologist once they reach
18 years of age. Large long-term randomized controlled trials are needed to establish the long-term safety issues of statins.
P L A I N L A N G U A G E S U M M A R Y
Statins for children with inherited high blood cholesterol
Review question
We reviewed the evidence for the effectiveness and safety of statins in children with inherited high blood cholesterol.
Background
Familial hypercholesterolemia is an inherited disease in which the blood cholesterol level is high. Vascular disease, i.e. furring up of the
blood vessels, often occurs at an earlier age than usual, especially amongst men. Thus lifelong therapies, started in childhood, to reduce
blood cholesterol are needed. In children with familial hypercholesterolemia, diet has been the main treatment option. Medications,
such as cholestyramine and colestipol, have been used effectively, but due to their unpleasant taste they are poorly tolerated and treatment
plans are not followed. The advent of statin therapy for children has improved treatment and this review updates the previous published
version.
Search date
The evidence is current to: 20 February 2017.
Study characteristics
The review included 9 studies with 1177 people with heterozygous familial hypercholesterolemia aged between 4 and 18 years of age.
Studies compared different statin treatments with a substance which contains no medication (termed placebo) and people were selected
for one treatment or the other randomly. The studies lasted from 12 weeks to 104 weeks.
Key results
In general, the intervention and follow-up time was short (median 24 weeks; range from six weeks to two years). Statins reduced the
mean low-density lipoprotein cholesterol concentration at all time points (moderate quality evidence). The levels of the liver enzymes,
serum aspartate and alanine aminotransferase, and the muscle enzyme, creatinine kinase, did not differ between treated and placebo
groups at any time point (low quality evidence). The risks of myopathy (disease of muscle tissue) and side-effects were very low and
similar in both groups (low quality evidence). Two of the statins, simvastatin and pravastatin, were shown to have a positive effect on
two of the major blood vessels typically affected by raised cholesterol levels (low quality evidence).
Quality of the evidence
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Blinding (performance bias and detection bias) was not present in any studies. In two studies information on how the participants were
allocated to treatment groups (selection bias) was clearly presented, but this information was not clearly stated in the remaining seven
studies. There is a lack of information whether investigators knew which treatment group participants would be put into (selection
bias) and or whether selective reporting (reporting bias) occurred, but it is very unlikely. In conclusion, it can be stated all the studies
appeared to be well run and we do not think any of the above-mentioned factors influenced the results in a negative way. Quality of
evidence varied frommoderate (change in serum low-density lipoprotein (LDL) cholesterol and adverse events) to low (change in blood
vessel wall (carotid intima-media) thickness, change in measures if growth and maturation, liver dysfunction, myopathy and change in
blood wall (endothelial) function).
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Statins compared with placebo for children with familial hypercholesterolemia
Patient or population: children with familial hypercholesterolemia
Settings: outpat ients
Intervention: stat ins
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Statins
Change in carotid in-
tima-media thickness
(mm) - At 2 years
Follow-up: 2 years
The mean change in
carot id int ima-media
thickness was 0.005
mm in the placebo
group
The mean change in
carot id int ima-media
thickness was 0.01 mm
lower (0.03mm lower to
0.00mm lower) in the
stains group
NA 211
(1 study)
⊕⊕©©
low1
Change in serum LDL
cholesterol level (%) -
At end of follow-up
Follow-up: up to 48
weeks
The mean change in
serum LDL cholesterol
level ranged f rom a 5%
increase to a 4% de-
crease across placebo
groups
The mean change in
serum LDL cholesterol
level was
32.15% lower (34.90%
lower to 29.40% lower)
in the stains group
NA 669
(6 studies)
⊕⊕⊕©
moderate1,2
Heterogeneity: I² = 89%
This outcome was also
reported at at 1 month
(228 part icipants, 3
studies), 6 months (528
part icipants, 4 studies)
and at 1 year (254
part icipants, 2 studies).
All pooled results were
in favour of stat ins;
the latter two analyses
were also very hetero-
geneous (I² > 85%)
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Change in measures
of growth and matura-
tion: change in puberty
proportion with Tanner
stage
>
= 1 level - At 2
years
Follow-up: 2 years
636 per 1000 604 per 1000
(489 to 750 per 1000)
RR 0.95 (95%CI 0.77 to
1.18)
211
(1 study)
⊕⊕©©
low1,3
This outcome was also
reported at at 6 months
(355 part icipants, 2
studies) and at 1 year
(139 part icipants, 1
study)
Results of analysis at
all t ime points showed
no signif icant dif f er-
ences between stat ins
and placebo
Liver dysfunction: pro-
portion with changed
aspartate aminotrans-
ferase or alanine
aminotransferase lev-
els (> 3x ULN) - At all
time points
Follow-up: up to 2 years
There were two cases
of changed aspartate
aminotransferase lev-
els and no cases of
changed alanine amino-
transferase levels in the
placebo groups (at all
t ime points)
There were four cases
of changed aspartate
aminotransferase lev-
els and four cases of
changed alanine amino-
transferase levels in the
stat ins groups (at all
t ime points)
See comment up to 9244
(7 studies)
⊕⊕©©
low1,5
There were no signif -
icant dif f erences be-
tween the number of
cases at any t ime point
for either measurement
and conf idence inter-
vals of pooled results
were wide due to very
low numbers of events
Myopathy: proportion
with changed serum
creatine kinase levels
(>10x ULN) - At all time
points
Follow-up: up to 1 year
There were two cases
of changed serum crea-
t ine kinase levels in the
placebo groups (at all
t ime points)
There were f ive cases
of changed serum crea-
t ine kinase levels in the
placebo groups (at all
t ime points)
See comment up to 6694
(6 studies)
⊕⊕©©
low1,5
There were no signif -
icant dif f erences be-
tween the number of
cases at any t ime point
and conf idence inter-
vals of pooled results
were wide due to very
low numbers of events
Change in endothe-
lial function: Change in
flow-mediated dilata-
tion of brachial artery
(%)
Follow-up: up to 1 year
The mean change in
f low-mediated dilata-
t ion of brachial artery
was 1.2%in the placebo
group
The mean change in
f low-mediated dilata-
t ion of brachial artery
was 2.70% higher (0.
42% to 4.98% higher) in
the stat ins group
NA 50
(1 study)
⊕⊕©©C
low1
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Adverse events - At
one year
Follow-up: up to 1 year
399 per 1000 402 per 1000
(323 to 502 per 1000)
RR 1.01 (95%CI 0.81 to
1.26)
276
(2 studies)
⊕⊕⊕©
moderate1
This outcome was also
reported at at 1 months
(248 part icipants, 2
studies) and at 6
months (416 part ici-
pants, 3 studies)
Results of analysis at
all t ime points showed
no signif icant dif f er-
ences between stat ins
and placebo
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; NA: not applicable; RR: risk rat io; ULN: upper lim it of normal
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
1. Downgraded once due to unclear risk of bias: methods of allocat ion concealment not described for any included studies
and method of randomisat ion not described for more than half of the included studies.
2. Downgraded once due to inconsistency: a large amount of stat ist ical heterogeneity present, despite studies being clinically
comparable.
3. Downgraded once due to applicability: unclear whether changes in puberty are due to a treatment ef fect of the stat ins or
due to natural changes in puberty of the age group.
4. Some studies contributed data to more than one t ime point, part icipants only counted once at the f irst t ime point reported.
5. Downgraded once due to imprecision: wide conf idence intervals of pooled ef fects due to very low numbers of events.
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B A C K G R O U N D
Description of the condition
Familial hypercholesterolemia (FH) is one of the most common
inherited metabolic diseases and, as an autosomal dominant con-
dition, may be either homozygous or heterozygous. Homozygous
FH is the more severe form with a prevalence of at least one case
in a million but will not be considered in this review. The average
worldwide prevalence of heterozygous FH individuals has been es-
timated to be at least about 1 in 500 individuals (Goldstein 1995;
Nordestgaard 2013), although recent genetic epidemiological data
from Denmark and next generation sequencing data suggest the
frequency may be closer to 1 in 250 (Sjouke 2015; Benn 2016;
Khera 2016; Pang 2016; Wald 2016). Mutations in one of three
genes that encode proteins involved in clearance of low-density
lipoprotein (LDL) cholesterol from the blood are known to cause
FH. The most common mutations in FH diminish the number
of cellular LDL receptors (LDLR) and render their function de-
fective. This results in a lifelong elevation of serum LDL choles-
terol which is two- to three-fold higher among FH heterozygotes
than among non-FH people. the other two known causative mu-
tations are the apolipoprotein B (APOB) gene that causes defective
binding of the LDL particle to the LDL-receptor and the gain of
function mutation in the proprotein convertase subtilisin/kexin
9 (PCSK9) gene. Currently, over 1700 different LDLR mutations
have been reported (Leigh 2016) but only one common APOB
and one common PCSK9 mutation are seen (Humphries 2006a).
Serum LDL cholesterol levels in untreated FH children are typi-
cally above 4 mmol/L (Wray 1996).
Coronary stenosis has been detected in men with FH as young
as 17 years and in women with FH as young as 25 years of
age (Mabuchi 1989). Indeed, early atherosclerosis, as determined
by increased carotid intima-media thickness, is detectable in un-
treated FH children from the second decade of life (Tonstad 1996;
Hoffmann 2002; Wiegman 2004).
Description of the intervention
It is necessary to start lifelong lipid-loweringmeasures in childhood
in order to reduce the risk of cardiovascular disease in later life.
Diet has so far been the main mode of treatment for children with
FH (Poustie 2001;McCrindle 2012). Anion exchange resins, such
as cholestyramine and colestipol, have been found to be effective
but are unpalatable, poorly tolerated and therefore poorly adhered
to by the patients (O’Connor 1990; Tonstad 1996).
Statins (3-hydroxy-3-methyl-glutaryl coenzyme A reductase in-
hibitors), are inhibitors of the rate-controlling enzyme in choles-
terol synthesis, and have been available for lowering plasma LDL
levels since the 1980s (Goldstein 1979; Goldstein 1990). Since
the 1990s studies with statins have been carried out amongst chil-
dren with FH aged 6 to 17 years and demonstrated a significant
reduction in LDL levels (Knipscheer 1996).
Why it is important to do this review
Themajor serious side-effect of statin therapy ismyopathy, defined
as muscle pain with serum creatine kinase concentrations of more
than1000Uper liter and in its extreme form rhabdomyolsis. These
fortunately occur rarely (Bradford 1991; Joy 2009) and statins
appear to be safe and well-tolerated in adults. While there is no
evidence these adverse effects occur more commonly in children
than adults, the long-term safety of statins amongst children is not
well documented.
This review is an update of previously published versions of this
Cochrane Review (Vuorio 2010; Vuorio 2014).
O B J E C T I V E S
To assess the effectiveness and safety of statins in children with
heterozygous FH.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized and non-randomized but controlled clinical studies
with systematic allocation.
Types of participants
Children and adolescents aged up to 18 years of age (at start of
study) with clinical diagnosis of heterozygous FH based on genetic
testing or clinical criteria (the level of serum total cholesterol is
higher than the age-adjusted normal upper limit and at least one
parent has been diagnosed with hypercholesterolemia).
Types of interventions
Active treatment with a statin (e.g. lovastatin, simvastatin, pravas-
tatin, fluvastatin, rosuvastatin, atorvastatin, pitavastatin) com-
pared to control treatment with another statin, or with placebo,
or with other lipid-lowering agents (fibric acids, resins), or with
diet alone or with no treatment.
7Statins for children with familial hypercholesterolemia (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Types of outcome measures
The ultimate goal of treatment with statins is to reduce the in-
cidence of morbidity and mortality from cardiovascular diseases.
These outcomes are rare in childhood, therefore, we used surro-
gate end points for assessing effectiveness. The ’change’ means the
difference between the values at the beginning and at the end of
follow-up. We report the means of both absolute (mmol/L) and
relative (%) changes in lipids between groups.
We grouped outcome data into those measured at one month, at
six months (± two weeks), at one year (± four weeks) and at two
years. These are time points commonly used in clinical studies for
evaluating drug effects and there was no statin-specific reason for
the selection.
Primary outcomes
1. Change in carotid intima-media thickness
2. Change in serum LDL cholesterol level
3. Change in measures of growth and maturation, e.g. age of
onset of puberty
Secondary outcomes
1. Liver dysfunction: change in aspartate aminotransferase
(AST) and alanine aminotransferase (ALT) levels
2. Myopathy: change in serum creatine kinase (CK) levels
3. Rhabdomyolysis (degeneration of skeletal muscle tissue) or
death due to rhabdomyolysis
4. Change in endothelial function (measured by flow-
mediated dilation of the brachial artery)
5. Change in serum total and high-density lipoprotein (HDL)
cholesterol and triglyceride (TG) level
6. Quality of life
7. Compliance to study medication
8. Other adverse events which may be associated with statins
Search methods for identification of studies
There were no restrictions regarding language or publication sta-
tus.
Electronic searches
Relevant studies were identified from the Group’s Inborn Errors
of Metabolism Trials Register us-
ing the terms: (*Hypercholesterolemia*:ti,ab,kw,mh,emt,misc1)
AND (*Statin*:ti,ab,kw,mh,emt,misc 1).
The Inborn Errors of Metabolism Trials Register is compiled from
electronic searches of the Cochrane Central Register of Controlled
Trials (CENTRAL) (updated with each new issue of the Cochrane
Library), weekly searches ofMEDLINE and the prospective hand-
searching of one journal - Journal of Inherited Metabolic Disease.
Unpublished work is identified by searching through the abstract
books of the Society for the Study of Inborn Errors of Metabolism
conference and the SHS Inborn Error Review Series. For full de-
tails of all searching activities for the register, please see the relevant
section of the Cochrane Cystic Fibrosis and Genetic Disorders
Group’s website.
Date of most recent search: 20 February 2017.
Searching other resources
Additionally, we searched the references of retrieved reviews and
original articles.
Data collection and analysis
Selection of studies
Two authors (AV, JK) independently assessed potentially eligible
studies for their suitability for inclusion in the review. We resolved
any disagreements by discussion.
Data extraction and management
The same two authors (AV, JK) independently extracted data from
the studies using a study selection and data extraction form mod-
ified for this review. We resolved any disagreements by discussion.
We present treatment with all statins combined as a single inter-
vention when comparing to control or placebo. We did not un-
dertake any formal subgroup analyses because the statins studied
differed between studies.
When study reports presented standard errors (SE), we converted
these to standard deviations (SD = SE x¬ square root of n). For
several outcomes for one study, we combined the results of three
intervention groups by using n-weighted averages of means and
SDs (Knipscheer 1996). The respective equations are described
in chapter 7 of theCochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011a).
Assessment of risk of bias in included studies
Weoriginally assessed themethodological quality of included stud-
ies based on a method as described by Jüni (Jüni 2001). We have
now related our judgements to the current Cochrane risk of bias
tool, so that assessments of adequate relate to low risk of bias, in-
adequate to high risk of bias and unclear to unclear risk of bias
(Higgins 2011b).
We independently assessed the following aspects of quality: gener-
ation of the allocation sequence (assessed as adequate, inadequate
or unclear); concealment of allocation (assessed as adequate, inad-
equate or unclear); the degree of blinding; and the appropriateness
of the statistical analyses (i.e. intention-to-treat or per protocol).
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Measures of treatment effect
For binary outcomes, the results are presented as risk ratios (RR)
with 95% confidence intervals (CIs). For continuous outcomes,
the results are presented as mean differences (MD) with 95% CIs.
Unit of analysis issues
There were no special unit-of-analysis issues. Cross-over and clus-
ter-randomized studies do not have a suitable design for the inter-
ventions being considered and we feel they are unlikely to be used
in the future.
Dealing with missing data
There were no or only few missing data in the included studies.
Assessment of heterogeneity
The I² statisticwas used to test the impact of heterogeneity between
studies (Higgins 2003). We considered levels of heterogeneity as
follows:
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%: may represent substantial heterogeneity;
• 75% to 100%: considerable heterogeneity.
Assessment of reporting biases
The use of a funnel plot to investigate the possibility of publication
bias was not feasible due to the small number of included studies;
for a funnel plot analysis, a minimum of 10 studies is required.
Data synthesis
Where feasible, we combined data using a fixed-effect model of
analysis.
Subgroup analysis and investigation of heterogeneity
We planned to explore possible sources of methodological het-
erogeneity, such as study quality or design and completeness of
follow-up. We also planned to consider possible sources of clini-
cal heterogeneity, such as sex and age of the participants and the
interventions being compared. We would have investigated these
using subgroup analyses; however, this was not feasible due to the
small number of included studies. If more studies are available for
future updates of this review and we identify heterogeneity, we
will consider undertaking those subgroup analyses listed above.
Summary of findings and quality of the evidence
(GRADE)
In a post hoc change from protocol, we have presented a summary
of findings tables for the comparison of statins versus placebo for
childrenwith FH (Summary of findings for themain comparison).
The following outcomes were reported in the tables (chosen based
on relevance to clinicians and consumers): change in carotid in-
tima-media thickness; change in serum LDL cholesterol level;
change in measures of growth and maturation, e.g. age of on-
set of puberty, liver dysfunction; change in aspartate and alanine
aminotransferase levels; myopathy; change in serum creatine lev-
els; change in endothelial function (measured by flow-mediated
dilation of the brachial artery); other adverse events which may be
associated with statins.
Outcomes were presented in the summary of findings table at the
end of follow-up or latest reported follow-up time.
We determined the quality of the evidence using the GRADE
approach; and downgraded evidence in the presence of a high
risk of bias in at least one study, indirectness of the evidence,
unexplained heterogeneity or inconsistency, imprecision of results,
high probability of publication bias. We downgraded evidence by
one level if they considered the limitation to be serious and by two
levels if very serious.
R E S U L T S
Description of studies
For further details please see the tables (Characteristics of included
studies; Characteristics of excluded studies).
Results of the search
We found 25 potentially eligible studies of statins for treating chil-
dren with FH. Nine randomized controlled studies were eligible
for inclusion. Reasons for excluding the remaining studies are pro-
vided in a table (Characteristics of excluded studies).
Included studies
Statins versus placebo
Nine randomized placebo-controlled studies were included, with
a total of 1177 children. The earliest study was published in
1996 (Knipscheer 1996) and the most recent in 2015 (Braaskamp
2015a).
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Study design
Six studies had a multicentre design (Stein 1999; de Jongh 2002a;
McCrindle 2003; Clauss 2005; Avis 2010; Braaskamp 2015a); the
remaining studies were undertaken at a single centre (Knipscheer
1996;Couture 1998;Wiegman 2004). The studies included a run-
in phase with a fat-restricted diet lasting from four weeks to three
months.OnlyWiegman averaged twomeasurements to obtain the
baseline LDL cholesterol level (Wiegman 2004), all other studies
carried out a single measurement.
The sizes of the study populations varied. Four studies had more
than 100 children per treatment arm (de Jongh 2002a; McCrindle
2003; Wiegman 2004; Avis 2010). The remaining studies were
much smaller, with group sizes ranging from 18 to 64. In general,
the intervention and follow-up time was short, median 24 weeks
(range from six weeks to two years).
Study participants
As inclusion criteria, three studies defined lower and upper limits
for LDL cholesterol, required the participant to be at Tanner stage
II (small amount of long, downy hair with slight pigmentation at
the base of the penis and scrotum or on labia majora) or higher at
the start of the study, and required FH to be present in the family
(Stein 1999; McCrindle 2003; Clauss 2005). Three studies had
criteria for LDL cholesterol lower limits and required FH to be
present in the family but did not have any criteria for sexual de-
velopment (Knipscheer 1996; de Jongh 2002a; Wiegman 2004).
One study based the inclusion on LDL cholesterol level and a pos-
itive DNA diagnosis of the participating child (Couture 1998). In
addition, McCrindle had a criterion for the upper level of serum
TG levels (McCrindle 2003); Wiegman required a positive DNA
diagnosis in the first-degree relative of the participating child and
used premature CVD in close relatives as an inclusion criterion
(Wiegman 2004); and Knispcheer required that clinical manifes-
tations of premature atherosclerosis had to be present before the
age of 50 years in the first or second-degree relatives (Knipscheer
1996). In one study either DNA-based or clinical criteria were
required in addition to specific criteria for the fasting LDL choles-
terol value and for female Tanner stage (Avis 2010). In the most
recent study either documented genetic effect or LDL-C
>
= 160
mg/dL or LDL-C > 130 mg/dL and male, early CVD in family,
HDL-C < 45mg/dL, TG > 150mg/dL, lipoprotein(a) > 75 nmol/
L, type 2 diabetes mellitus diagnosed and blood pressure > 95th
percentile for age and height were required (Braaskamp 2015a).
Exclusion criteria were aimed at excluding children with concomi-
tant diseases which elevate lipid levels or medications that could
interact with statins and thus included homozygous FH; diabetes
mellitus; anorexia nervosa; kidney, liver or thyroid disorders; con-
comitant other dyslipidemias; immunosuppressant drugs; or drugs
that are potent inhibitors of cytochrome P-450 3A4. Lifestyle was
not generally considered at inclusion, e.g. there were no criteria re-
garding alcohol consumption and only one study excluded smok-
ers.
The age of the study participants ranged from 6 years to 18 years;
51% were males. The mean (SD) baseline LDL cholesterol in the
study groups varied from 5.28 (1.08) mmol/L (de Jongh 2002a)
to 6.48 (0.98) mmol/L (Stein 1999).
Study interventions
Two studies used lovastatin with daily doses of 40 mg (Stein 1999;
Clauss 2005), one pravastatin with doses of 5 mg to 20 mg (
Knipscheer 1996), one pravastatin with doses of 20 mg to 40 mg
(Wiegman 2004), one simvastatin with a dose of 20 mg (Couture
1998), one simvastatin with a dose of 40 mg (de Jongh 2002a),
one atorvastatin with doses of 10 mg to 20 mg (McCrindle 2003),
one rosuvastatin with doses of 5 mg to 20 mg (Avis 2010) and one
pitavastatin with doses of 1 mg to 4 mg (Braaskamp 2015a).
Outcome measures
Only four studies mentioned compliance as monitored by count-
ing tablets (Couture 1998; Wiegman 2004; Clauss 2005; Avis
2010). Although one important exclusion criterion was the use
of drugs that are potent inhibitors of cytochrome P-450 3A4 like
macrolide antibiotics and ketoconazole, it was unclear how their
use was monitored and avoided.
Changes in LDL cholesterol during the treatment were measured
in all studies. The primary efficacy outcome in eight studies was
an absolute or percentage change in LDL cholesterol (Knipscheer
1996; Couture 1998; Stein 1999; de Jongh 2002a; McCrindle
2003; Clauss 2005; Avis 2010; Braaskamp 2015a). In one study
it was the change from baseline in mean carotid intima-media
thickness (IMT) (Wiegman 2004). Four studies reported absolute
LDL cholesterol concentrations and the mean percentage change
in LDL cholesterol at the end of follow-up (Knipscheer 1996;
McCrindle 2003; Clauss 2005; Avis 2010) and one reported the
mean percentage change in LDL cholesterol (Couture 1998;). Of
the studies reporting absolute and mean percentage change, two
reported the mean percentage change in LDL cholesterol at the
end of follow-up (Stein 1999; de Jongh 2002a), one reportedmean
percentage change but not SD for this change (Braaskamp 2015a),
one reported the mean absolute changes in LDL cholesterol dur-
ing follow-up (Wiegman 2004), and one reported the relative dif-
ference between the mean LDL values in the beginning and at the
end of the study (Avis 2010). The study of Wiegman was there-
fore excluded from the follow-up LDL cholesterol analyses, which
were carried out either by using LDL cholesterol concentrations
or percentage reduction at the end of the follow-up. Five studies
explicitly reported that they used the Friedewald formula to calcu-
late LDL cholesterol (Knipscheer 1996; Couture 1998; Wiegman
2004; Clauss 2005; Avis 2010).
Clinically significant elevation in hepatic transaminase (AST or
ALT) levels, possibly related to hepatotoxicity, was defined as more
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than three times the upper limit of normal (ULN). This measure-
ment was reported in eight studies (Knipscheer 1996; Stein 1999;
de Jongh 2002a; McCrindle 2003; Wiegman 2004; Clauss 2005;
Avis 2010; Braaskamp 2015a). Clinically significant CK elevation
related to possible myopathy or rhabdomyolysis (or both) was de-
fined as more than 10 times the ULN. This measurement was
reported in seven studies (Knipscheer 1996; Stein 1999; de Jongh
2002a; McCrindle 2003; Clauss 2005; Avis 2010; Braaskamp
2015a).
The effect of statins on puberty (defined as an increase in the Tan-
ner stage) was reported in only three studies (de Jongh 2002a;
McCrindle 2003; Wiegman 2004). Height and weight measure-
ments were carried out in some studies, but due to the short fol-
low-up time, it is not possible to draw any further conclusions on
their changes and are not examined in the present analysis.
Six studies reported adverse events (Knipscheer 1996; Stein 1999;
de Jongh 2002a; McCrindle 2003; Clauss 2005) with one not
separating treated participants from controls (Braaskamp 2015a).
Muscular adverse events were reported as either myalgia or my-
opathy.
Given cholesterol is a precursor of steroid and sex hormones, four
studies reported the results of plasma levels of these hormones
(Stein 1999; de Jongh 2002a; Wiegman 2004; Clauss 2005). The
differences between the treatment and placebo groups, although
statistically significant, were small. Normal variability of these hor-
mones is large at this age; thus we considered the differences to be
of no clinical significance but exact significance is unknown.
Change in thickness of carotid intima was examined in only one
study (Wiegman 2004).
There were no reports on quality of life.
Excluded studies
Of the 17 excluded studies, 13 did not have controls (Lambert
1996; Raal 1997; Stein 1999; Athyros 2002; Dirisamer 2003;
Hedman 2003; Sinzinger 2004; Hedman 2005; van der Graaf
2006; Carreau 2011; Gandelman 2011; Braaskamp 2015b;
Langslet 2016), one was carried out with a combination of
colestipol resin and a statin (McCrindle 2002), one did not have
clearly defined controls (Stefanutti 1999), one was not random-
ized (Braaskamp 2015c) and in one participants had homozygous
FH (Stein 2016).
Risk of bias in included studies
In the original version of this review, methodological quality was
assessed based on a method as described by Jüni (Jüni 2001). We
primarily focused on the following aspects of study design:method
and concealment of allocation, treatment and control group com-
parability at baseline, use of intention-to-treat analysis, and blind-
ing. Loss to follow-up was reported heterogeneously and was diffi-
cult to grade. There was no indication to suspect selective report-
ing in any of the studies. For this update, these judgements have
been related to the current risk of bias tool as described in chapter
8 of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011b). Please refer to the risk of bias graph (Figure 1).
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Figure 1. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Generation of allocation sequence
The generation of the allocation sequence was adequate in two
studies since the sequence was computer-generated (Wiegman
2004; Clauss 2005). In two studies (unclear risk), it was stated
that groups were stratified but the randomization procedure was
not described (Knipscheer 1996; Avis 2010). The remaining five
studies were described as randomized, but no further details of the
process were given (also unclear risk of bias) (Couture 1998; Stein
1999; de Jongh 2002a; McCrindle 2003; Braaskamp 2015a).
Concealment of allocation
None of the included studies described how the allocation se-
quence was concealed from the investigators, the outcome asses-
sors or the participants in the study (unclear risk of bias). However,
one study (Avis 2010) reported randomisation was stratified by
center, and there was one multicenter study (Braaskamp 2015a);
both of these were assumed to have been centrally randomised.
Blinding
All studies were described as double blind, indicating that partici-
pants and those participating in treatment procedureswere blinded
to treatment (low risk).
Incomplete outcome data
Dropout rates were reported in seven studies (low risk of bias)
(Stein 1989; de Jongh 2002a; McCrindle 2003; Wiegman 2004;
Clauss 2005; Avis 2010; Braaskamp 2015a); these were low, vary-
ing from 2% (McCrindle 2003) to 8% (Stein 1999). Two studies
did not present a report on dropout rates (unclear risk of bias)
(Knipscheer 1996; Couture 1998).
Effects of interventions
See: Summary of findings for the main comparison
Please refer to the ’Summary of Findings table’ for explanations
of the assessments of the quality of the evidence (Summary of
findings for the main comparison).
Statins versus placebo
Primary outcomes
1. Change in thickness of carotid intima
One study reported on this outcome (Wiegman 2004). This study
showed that two years of pravastatin therapy induced a small but
significant regression of IMT compared to placebo which was -
0.01 mm (95%CI -0.03 to -0.00) (low quality evidence) (Analysis
1.1).
2. Change in serum LDL cholesterol level
Five studies reported the difference between mean relative reduc-
tions of serumLDL cholesterol levels (de Jongh 2002a; Knipscheer
1996; Stein 1999; McCrindle 2003; Clauss 2005). One study re-
ported only changes in absolute lipid levels (Wiegman 2004), one
study reported lipid levels in graph form only (Couture 1998);
LDL cholesterol data from these two studies were not analysed.
One study reported LDL cholesterol levels using the relative dif-
ference between the mean LDL values in the beginning and at the
end of the study (Avis 2010) and one study reported LDL choles-
terol mean percentage change without SD (Braaskamp 2015a).
At one month (three studies) the pooled estimate of the difference
in mean relative reductions was -24.59% (95% CI -30.11 to -
19.08) (Braaskamp 2015a; Clauss 2005; Knipscheer 1996), at six
months (four studies) it was -34.97% (95% CI -37.51 to -32.44)
(Clauss 2005; de Jongh 2002a; McCrindle 2003; Stein 1999) and
at one year (two studies) it was -26.94% (95% CI -31.64 to -
22.23) (de Jongh 2002a; Stein 1999) (Analysis 1.2).
The difference inmean relative reductions in LDL cholesterol con-
centration at end of follow-up (median 24 weeks) between those
treated with statins and those with a placebo varied from -21% to -
41%.The pooled estimate of the difference inmean relative reduc-
tions at the end of follow-up (six studies) was -32.15% (95% CI -
34.90 to -29.40) (moderate quality evidence) (Braaskamp 2015a;
Clauss 2005; de Jongh 2002a; Knipscheer 1996;McCrindle 2003;
Stein 1999) (Analysis 1.2).
The studies can be considered clinically comparable even though
the results showed statistical heterogeneity. This heterogeneity was
present at six months (I² = 86%) and at one year (I² = 81%), but
not at one month. The heterogeneity is most likely due tomultiple
factors such as variation in statin type, statin dosage and duration
of study.
3. Change in measures of growth and maturation
Three studies reported measures of growth (de Jongh 2002a;
McCrindle 2003;Wiegman 2004). The effect of statins onpuberty
was measured by the change in Tanner stage. McCrindle reported
percentage of groups experiencing an increase in Tanner stage and
we calculated the number of events from this in order to enter
data into the meta-analysis. The pooled estimate of the RR at six
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months (two studies) was -0.99 (95% CI -0.66 to 1.50) (de Jongh
2002a; McCrindle 2003), at one year (one study) 0.89 (95% CI
0.51 to 1.54) (de Jongh 2002a) and at two years (one study) 0.95
(95% CI 0.77 to 1.18) (low quality evidence) (Wiegman 2004)
(Analysis 1.3).
Secondary outcomes
1. Liver dysfunction
a. Change in AST levels
Seven studies reported levels of AST (Knipscheer 1996; Stein
1999; de Jongh 2002a; McCrindle 2003; Wiegman 2004; Clauss
2005; Braaskamp 2015a). At one month there were no cases re-
ported (Braaskamp 2015a; Knipscheer 1996), at six months (four
studies) the estimate of the RR was 2.40 (95% CI 0.29 to 19.85)
(Clauss 2005; de Jongh 2002a; McCrindle 2003; Stein 1999), at
one year (two studies) 2.03 (95% CI 0.08 to 49.09) (de Jongh
2002a; Stein 1999) and at two years (one study) 0.21 (95% CI
0.01 to 4.23) (low quality evidence) (Wiegman 2004) (Analysis
1.4).
b. Change in ALT levels
Seven studies reported levels of ALT (Stein 1989; Knipscheer
1996; de Jongh 2002a; McCrindle 2003; Wiegman 2004; Clauss
2005; Braaskamp 2015a). There were no cases reported at one
month (Braaskamp 2015a; Knipscheer 1996) or at two years (
Wiegman 2004). At six months (four studies) the estimate of the
risk ratio was 2.03 (95%CI 0.24 to 16.95) (Clauss 2005; de Jongh
2002a;McCrindle 2003; Stein 1999) and at one year (two studies)
2.03 (95% CI 0.08 to 49.09) (low quality evidence) (de Jongh
2002a; Stein 1999) (Analysis 1.5).
2. Myopathy: change in serum CK levels
Six studies reported the change in serum CK levels (Stein 1989;
Knipscheer 1996; de Jongh 2002a; Clauss 2005; Avis 2010;
Braaskamp 2015a). At one month (three studies) the pooled es-
timate of the RR was 3.23 (95% CI 0.18 to 58.84) (Avis 2010;
Braaskamp 2015a; Knipscheer 1996), at six months (two studies)
it was RR 0.22 (95% CI 0.01 to 5.28) (Clauss 2005; de Jongh
2002a) and at one year (two studies), RR 0.67 (95% CI 0.04
to 10.57) (low quality evidence) (de Jongh 2002a; Stein 1999)
(Analysis 1.6).
3. Rhabdomyolysis
There were no reported cases of rhabdomyolysis.
4. Change in endothelial function
The change in endothelial function was reported in a sub-study
of the 2002 de Jongh study, among 28 participants treated with
statins and 22 treatedwith placebo (de Jongh 2002a). The absolute
change in relative flow-mediated dilatation of brachial artery was
2.70% (95% CI 0.42 to 4.98) (low quality evidence) (de Jongh
2002a) (Analysis 1.7).
5. Change in serum total cholesterol, HDL cholesterol and
TG levels
a. Change in serum total cholesterol levels
Five studies reported the difference between mean relative reduc-
tions of serum total cholesterol levels (Stein 1989; Knipscheer
1996; de Jongh 2002a;McCrindle 2003; Clauss 2005).One study
reported mean relative reductions of serum total cholesterol levels
but not the SDs (Braaskamp 2015a).
At one month (three studies) the pooled estimate of the difference
in mean relative reductions was -18.31% (95% CI -22.55 to -
14.06) (Braaskamp 2015a; Clauss 2005; Knipscheer 1996), at six
months (four studies) -24.28% (95%CI -26.09 to -22.47) (Clauss
2005; de Jongh 2002a; McCrindle 2003; Stein 1999) and at one
year (two studies) -27.60% (95% CI -30.64 to -24.57) (de Jongh
2002a; Stein 1999) (Analysis 1.8).
The difference inmean relative reductions in total cholesterol con-
centration at the end of the follow-up (median 24 weeks) between
those treated with a statin and those with a placebo varied from -
17% to -32%. The pooled estimate of the difference in mean rel-
ative reductions at the end of follow-up (six studies) was -26.53%
(95% CI -28.54 to -24.51) (Braaskamp 2015a; Clauss 2005; de
Jongh 2002a; Knipscheer 1996; McCrindle 2003; Stein 1999)
(Analysis 1.8).
The studies can be considered clinically comparable even though
the results showed statistical heterogeneity. This heterogeneity was
not present at one month, but it was present at six months (I² =
87%) and at one year (I² = 95%).
b. Change in serum HDL cholesterol levels
Five studies reported the difference between mean relative reduc-
tions of serum HDL cholesterol levels (Knipscheer 1996; Stein
1999; de Jongh 2002a; Clauss 2005;McCrindle 2003).One study
reported HDL cholesterol levels using the relative difference be-
tween the mean HDL values in the beginning and at the end of
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the study (Avis 2010) and one study reported mean percentage
change in HDL cholesterol without SD (Braaskamp 2015a).
At one month (three studies) the pooled estimate of the difference
in mean relative change was 3.00% (95% CI -2.47 to 8.47) (
Braaskamp 2015a; Clauss 2005; Knipscheer 1996), at six months
(four studies) 4.18% (95% CI 1.54 to 6.82) (Clauss 2005; de
Jongh 2002a; McCrindle 2003; Stein 1999) and at one year (two
studies) 2.56% (95% CI -1.17 to 6.29) (de Jongh 2002a; Stein
1999) (Analysis 1.9).
The difference in mean relative reductions in HDL cholesterol
concentration at the end of the follow-up (median 24 weeks) be-
tween those treated with statins and those with a placebo varied
from 0% to 5%. The pooled estimate of the difference in mean
relative changes at the end of follow-up (six studies) was 3.11%
(95% CI 0.55 to 5.67) (Braaskamp 2015a; Clauss 2005; de Jongh
2002a; Knipscheer 1996; McCrindle 2003; Stein 1999) (Analysis
1.9).
c. Change in serum TG levels
Four studies reported the difference between mean relative re-
ductions of serum TG levels (Knipscheer 1996; Stein 1999;
McCrindle 2003; Clauss 2005). One study reported TG levels
using the relative difference between the mean TG values in the
beginning and at the end of the study (Avis 2010) and one study
reported mean percentage change without the SD (Braaskamp
2015a).
At one month (three studies) the pooled estimate of the difference
in mean relative change was 10.31% (95% CI -5.11 to 25.74)
(Braaskamp 2015a; Clauss 2005; Knipscheer 1996), at six months
(three studies) -9.34% (95% CI -18.90 to 0.22) (Clauss 2005;
McCrindle 2003; Stein 1999) and at one year (one study) 0.00%
(95% CI -18.09 to 18.09) (Stein 1999) (Analysis 1.10).
The difference in the mean relative reductions in TG concentra-
tion at the end of follow-up (median 24 weeks) between those
treated with statins and those with a placebo varied from -7% to
16%. The pooled estimate of the difference in mean relative re-
ductions at the end of follow-up (five studies) was -3.27% (95%
CI -12.03 to 5.50) (Braaskamp 2015a; Clauss 2005; Knipscheer
1996; McCrindle 2003; Stein 1999) (Analysis 1.10).
6. Quality of life
No study reported this outcome.
7. Compliance
Compliance was reported in one study by tablet counting
(Wiegman 2004) and it was found most children adhered to the
protocol, i.e. 84% of tablets were taken for the full length of the
two-year study.
8. Adverse events
Six studies reported clinical adverse events (Knipscheer 1996; Stein
1999; de Jongh 2002a;McCrindle 2003; Clauss 2005; Avis 2010).
At one month (two studies) the estimate of the RR was 0.86 (95%
CI 0.65 to 1.13) (Avis 2010; Knipscheer 1996), at six months
(three studies) 1.02 (95%CI 0.82 to 1.27) (Clauss 2005; de Jongh
2002a; McCrindle 2003) and at one year (two studies) 1.01 (95%
CI 0.81 to 1.26) (moderate quality evidence) (de Jongh 2002a;
Stein 1999) (Analysis 1.11).
D I S C U S S I O N
Summary of main results
We analysed nine randomised placebo-controlled studies in chil-
dren with heterozygous familial hypercholesterolaemia (FH). The
studies showed a clinically significant reduction in both serum
total cholesterol and low-density lipoprotein (LDL) cholesterol
among children treated with a statin compared with those treated
with a placebo. In addition, statin therapy slightly increased serum
high-density lipoprotein (HDL) cholesterol and slightly decreased
serum triglyceride concentration; however, when compared with
the substantial change in serum LDL cholesterol, these changes
are likely to be of minor importance. The magnitude of LDL
cholesterol lowering varied from study to study, most likely due
to different statins and doses and possibly due to different defini-
tions about true monogenic heterozygous FH. We did not do any
formal subgroup analyses because the choice of statin treatment
was heterogeneous between studies.
Endothelial dysfunction represents one of the earliest stages of
atherogenesis, and has a clear predictive value for future cardio-
vascular disease. A number of studies have shown that endothe-
lial function measured as flow-mediated dilation is impaired in
children with FH (de Jongh 2002b; Vlahos 2014). The effect of
simvastatin on flow-mediated dilatation of the brachial artery in
children with FH was reported in one study (de Jongh 2002a). It
was found that simvastatin therapy restored endothelial function
in the studied participants (50 children with FH; 9 to 18 years).
Clearly more studies are needed to confirm this result in children
with FH.
In addition to early changes in the function of the arterial en-
dothelium in children with FH, which result from the high LDL
cholesterol concentration in the blood, accumulation of the LDL
cholesterol in the subendothelial space of the carotid arterial wall
leads to increased intima-media thickness (IMT) of the carotid ar-
teries (Tonstad 1996). Carotid IMT represents the combined in-
tima and media thickness of the arterial wall, and numerous stud-
ies have shown that this surrogate marker of atherosclerotic vessel
wall change is a reliable indicator of clinical outcomes later in life
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(Koeijvoets 2005). Accordingly, studies examining the sensitivity
of this surrogate marker to risk intervention are important. We
found only one study that used carotid IMT as the primary effi-
cacy outcome in children with FH treated with statins (Wiegman
2004). The authors found that two years of pravastatin therapy
induced a small but significant regression in mean change in IMT
between statin-treated and placebo groups in children with FH.
This clearly encouraging result calls for further studies with pravas-
tatin or other statins.
In the largest study, all children were from families where a molec-
ular diagnosis had been made in one parent and where the re-
cruited child had LDL cholesterol twice greater than 4.0 mmol/
L. The authors judged this to mean the child had a greater than
99.6% chance of having inherited the family mutation (Wiegman
2004).This sample is therefore highly likely to consist of all FH
individuals. In the most recent study (Braaskamp 2015a), all chil-
dren had a mutation in LDLR or APOB genes or had a parent
where the mutation had been identified, and thus all of these chil-
dren have molecularly defined monogenic FH. In all the other
studies, children were recruited as having LDL cholesterol above
a cut-off point which varied between the studies (Starr 2008).
The other criterion was having a first degree relative, either with
elevated LDL cholesterol, or with a family history of premature
coronary artery disease. It is therefore likely the vast majority of
the children in the studies included in this review have monogenic
FH, but it cannot be ruled out that a small percentage (not more
than 10%) may not have.
Although in the majority of studies published in recent years
molecular testing was performed and only mutation-positive par-
ticipants recruited, the diagnosis of FH was not confirmed by di-
rect molecular testing of the children in some of the earlier studies
included in this review. Although idiopathic elevated LDL choles-
terol levels occur less frequently in children than in adults, this
raises the question of whether only a proportion of the children
in the earlier studies have true monogenic FH. This may affect
the conclusions made above, since the lipid-lowering response to
a statin may be different in mutation carriers compared to those
with a polygenic cause of their phenotype. In adults with a clinical
diagnosis of “Definite” FH a causative mutation can be found in
between 70% to 80% of individuals, while only around 30% of
people with a clinical diagnosis of “Possible” FH carry a causative
mutation (Graham 2005; Humphries 2006b; Futema 2013). It is
now known that in people with a clinical diagnosis of FH but with
no detectable mutation in any of the three common FH genes
there is a polygenic (not a monogenic) cause of their phenotype
(Talmud 2013), and they have been incorrectly been given the
diagnosis of FH. This polygenic cause has also been demonstrated
to explain the elevated LDL-C levels in children with a diagnosis
of FH where no mutation can be found (Futema 2015).
In the absence of molecular confirmation, it is possible to estimate
the probable dilution of monogenic FH children with children
with a polygenic aetiology from family studies. There is a consid-
erable overlap in LDL-cholesterol levels in the mutation-carrying
and non-mutation carrying siblings of a parent with FH, such that
using the intersection between the two peaks of LDL-cholesterol
levels observed results in a false positive diagnostic rate of 6% to
8% (Kwiterovich 1974; Leonard 1976). Thus selecting children as
“FH” based only on having a parent with FH and elevated LDL-C
levels may have resulted in the inclusion of 6% to 8% non-muta-
tion carriers, in earlier studies where no DNA testing was carried
out. Based on this we can conclude that the earlier published es-
timates of the effect of statin treatment in children with a clinical
diagnosis of FH where no molecular testing had been performed
are unlikely to have been significantly influenced by the incorrect
inclusion of non-monogenic individuals.
The importance of distinguishing between monogenic and poly-
genic elevation of LDL cholesterol is whether children with a
monogenic cause might have a much smaller than average LDL
cholesterol-lowering response than children whose hypercholes-
terolaemia is due to polygenic causes. Although we are not aware
of any data addressing this directly in children, there is evidence
that adults with a clinical diagnosis of FH without a detected mu-
tation have a better response to statins than those in which a mu-
tation has been found (Sun 1998; Heath 1999). Another issue
to consider is that children with different LDLR mutations, or in
those where FH is caused by mutations in the APOB or PCSK9
genes, may respond differently to statins. There is no direct evi-
dence for this in children, but adults carrying the APOB muta-
tion have been reported to respond better to statins than those
carrying an LDLR mutation (Myant 1993) or a PCSK9 muta-
tion (Humphries 2006b). Furthermore, the class of LDLR muta-
tion can affect the untreated LDL cholesterol levels (Humphries
2006b; Futema 2013) and affect the response to statins (Couture
1998; Vohl 2002;Miltiadous 2005). These variations according to
mutations are pertinent because founder effects are seen in many
countries, e.g. South Africa (Kotze 1993), Finland (Vuorio 2001)
andHolland, (Umans 2002). Thus the variability in the prevalence
of differentmutations andmolecular causes of FHacross countries
may contribute to a small extent to between-study differences in
response but although there may be a small overestimate of the
response in statin-sensitive mutation-carrying FH children, it is
unlikely to be more than 5% (van der Graaf 2011).
Recent guidelines vary in their recommendations as to when
statin treatment should be started between 8 years to 14 years
(McCrindle 2007; SIGN 2007; Daniels 2008; NICE 2008;
Descamps 2011; Goldberg 2011; Sullivan 2012). None of the
guidelines recommended statins before the age of eight years in
cases of heterozygous FH (Vuorio 2013). In regard to dosing, this
varied considerably between the studies. In the earliest study, chil-
dren with FH were treated with pravastatin doses from 5 mg/day
to 20 mg/day (Knipscheer 1996). In the later studies there was a
tendency to use larger doses. Wiegman used pravastatin doses of
20 mg/day or 40 mg/day (Wiegman 2004), and de Jongh titrated
simvastatin doses of up to 40 mg/day (equivalent dose of pravas-
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tatin, 80 mg/day) (de Jongh 2002a). McCrindle titrated atorvas-
tatin doses from 10 mg/day up to 20 mg/day (equivalent dose
of pravastatin, up to 80 mg/day) if the LDL cholesterol level re-
mained over 3.4 mmol/L (McCrindle 2003). In this study the
mean serum LDL cholesterol concentration among FH children
treated with statins was 3.39 mmol/L at the end of follow-up. In
the most recent study (Braaskamp 2015a), the 5 mg starting dose
of rosuvastatin was titrated at 3-monthly intervals to a maximum
tolerated dose of 10 mg (six- to nine-year olds) or 20 mg (10- to
17-year olds) to achieve an LDL-C goal of (2.85 mmol/L (110
mg/dL). In all cases the minimal effect dose is advised.
It has been estimated that elevations in aminotransferase levels
over three times the upper limit of normal occur in less than 1% of
adults on any statin (Cohen 2006). However, therewas no increase
in aminotransferase levels when compared with a placebo group in
a recent meta-analysis (de Denus 2004), and adults with elevated
aminotransferase levels during statin treatment do not appear to
have a higher risk of liver dysfunction (Chalasani 2004). The risk
of acute severe liver dysfunction in the general population with
no statin medication is about one to two cases per million (Law
2006). Consequently, severe liver dysfunction is extremely rare
and routine monitoring is recommended, but it will be effective
only when it is active and includes not only laboratory test but also
clinical follow-up (Golomb 2013). The studies of children with
FH used liver transaminases as the method for detecting possible
liver dysfunction. The putative risk of statin-induced severe acute
liver dysfunction at this stage of life should be outweighed by the
reduced cardiovascular risk achieved by statin treatment (NICE
2008). The most recent guidelines by the National Lipid Associ-
ation’s Statin Safety Assessment Task Force give some useful con-
siderations (McKenney 2006). They underline the importance of
monitoring any possible symptoms like abdominal pain related
to liver dysfunction and advise to consider using a fractionated
bilirubin for detection of liver dysfunction. This kind of monitor-
ing was carried out systematically in only half of the studies we
analyzed, and the monitoring protocol varied between the studies
(Stein 1999; de Jongh 2002a;Wiegman 2004; Clauss 2005).None
of the studies included fractionated bilirubin in their laboratory
analysis. It can be concluded that even though liver dysfunction
was not present in the included studies, the risk exists. Therefore,
any new studies of children with FH should be planned so that
possible hepatotoxicity symptoms are routinely monitored using
standardized methods and, additionally, new laboratory standards
should be used in detecting possible liver dysfunction.
The incidence of rhabdomyolysis has been estimated to be about
3.4 per 100,000 person-years in adults (Law 2006). Although this
figure is very low, the lesson learned with cerivastatin should be
keenly kept inmind (Pasternak 2002). The rate of fatal rhabdomy-
olysis with this drug was unexpectedly and exceptionally high;
16 to 80 times greater than with other statins (Staffa 2002) and
even after excluding individuals treated simultaneously with gem-
fibrozil, the rate of fatal rhabdomyolysis was still 10 to 50 times
higher than of other statins (Staffa 2002). All statins used so far in
children with FH (atorvastatin, lovastatin, pravastatin, and sim-
vastatin) appear to have a low risk of rhabdomyolysis as compared
to adults, which is estimated to be about 0.08% to 0.09% of per-
sons treated with these statins (Pasternak 2002). Since the mech-
anism of myopathy is not well understood, it is of the utmost
importance to monitor adverse reactions and adjust the therapy
accordingly (Pasternak 2002).
The terminology of clinical adverse events in the analyzed stud-
ies varied. The comparison between the studies would have been
more reliable if the definition of adverse events had been standard-
ized. It is important to note that some drugs that interact with
statins (macrolide antibiotics and azole fungals) may have been
consumed, thus altering the adverse event risk. In practice any
interaction risk can be mitigated with patient education. Statin
therapy combined with alcohol abuse potentially increases the risk
of liver dysfunction. Alcohol consumption was not monitored in
any of the included studies; however, alcohol abuse is uncommon
in children but when adolescence is reached discussions about al-
cohol consumption should be had with the young person. It is
unclear as to whether statins increase the risk of cataracts with
about equal numbers of studies supporting the theory versus those
against (Harris 1995; Cenedella 1996; Pedersen 1996; Chodick
2010; Hippisley-Cox 2010; Fong 2012; Leuschen 2013).
One of the potential long-term side effects of statin treatment in
children with FH is the increased risk of developing type 2 dia-
betes (T2D) that has been noted in statin treatment of non-FH
individuals. A meta-analysis of published randomised controlled
trials in over 91,000 high risk individuals from the general pop-
ulation (Sattar 2010) reported statin therapy was associated with
a 9% increase in the likelihood of new T2D during follow-up.
Interestingly, a second meta-analysis showed pravastatin (40 mg/
day) was associated with the lowest (7%), atorvastatin (80 mg/
day) with an intermediate (15%) and rosuvastatin (20 mg/day)
and simvastatin (40 mg/day) with the highest (25% and 21%
respectively) risk of new onset T2D (Navarese 2013). The exact
molecular mechanism of this statin-associated T2D risk is un-
known (please refer to the references in Vuorio 2016), and it is
unclear whether this is an on-target or off-target effect of the drug;
that is, whether the dysglycaemic effect is a direct consequence
of inhibition of HMG-CoA, the intended target of statins. Using
the approach of Mendelian Randomisation, variants in the gene
encoding HMG-CoA reductase (HMGCR, chr 5q13.3) associ-
ated with lower LDL-C were used as proxies for statin treatment.
Both statin treatment and the genetic variants were associated with
higher T2D risk and higher bodyweight, and the genetic variants
with higher plasma glucose and insulin, and waist and hip circum-
ferences (Swerdlow 2015). This directional concordance strongly
suggested that the higher T2D risk caused by statin therapy is at
least in part a direct consequence of HMG-CoA reductase inhibi-
tion. Reassuringly, many studies have reported that the prevalence
of T2D is low in adults with FH, and in a study of over 63,000
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people fromHolland (Besseling 2015), even in treated adults with
FH the prevalence of T2D was significantly lower than in their
unaffected relatives (1.75% versus 2.93%). Follow-up studies in
adults (Skoumas 2014) and in children (Kusters 2014) are also
reassuring, with 10-year follow-up in 194 statin-treated children
(mean age at baseline 13 years) seeing one new case of T2D, with
a similar incidence in their 83 non-FH siblings (Kusters 2014). It
is clear that overall the benefits of statin treatment for preventing
cardiovascular disease in people with FH far outweighs themodest
potential risk of T2D. It is possible the dietary and lifestyle advice
given to all people with FH encourages them to maintain an ideal
body weight and thus to ameliorate any of the statin-associated
risk of developing T2D. Based on published evidence it would ap-
pear that treatment with pravastatin is associated with the lowest
risk, although long-term follow-up studies of treated FH children
are needed to confirm this.
Relatively little is known about the potential statin-related neu-
rologic side-effects such as sleep disturbances (Bays 2006), effects
on cognitive function and peripheral neuropathy (Backes 2003;
Chong 2004). In most cases, the onset of symptoms was reported
within sixmonths of commencingmedication, andmost of the pe-
ripheral neuropathies were confirmed by nerve conduction stud-
ies. The reports were related to all statins, and discontinuation of
statin treatment improved the symptoms. In a recent review based
on adult studies, peripheral neuropathy was concluded to be an id-
iosyncratic effect of statin use (Brass 2006). In the included studies
Wiegman showed that there was no difference on academic per-
formance between the statin treated and placebo group (Wiegman
2004).
Particularly important are the concerns related to any potential im-
pact on sexual and physical maturation (McCrindle 2007). Long-
term effects on maturation will need to be studied in longer and
larger controlled follow-up studies. Physical maturation was fol-
lowed in some studies by measuring height but this is unreliable in
short-term studies. There is concern about pregnancy during statin
treatment (McCrindle 2007) as statins can affect foetal develop-
ment. Females of child-bearing age should receive counselling and
contraceptive advice (Arambepola 2007; McCrindle 2007; NICE
2008; Nordestgaard 2013).
In summary, this review found statins to be an effective treatment
for FH in children. It did not find any difference between the
statin and control group in the proportion of participants who
experienced a clinically significant increase in liver transaminase
values (over three-fold increase in alanine transferase or aspartate
aminotransferase) or creatine kinase values (over 10-fold increase).
We did not find any significant difference between those treated
with a statin and those treated with placebo with respect to their
sexual maturation measured by the Tanner staging. Overall, the
data suggest the risk of adverse events in children treated with
statins is similar to that observed in statin-treated adults over the
short term and the adverse event rate was the same between statin
and placebo group. In the absence of long-term treatment and
follow-up of children, it is not possible to rule out any long-term
adverse effects. Our findings are similar to those reported in two
systematic reviews (Arambepola 2007; Avis 2007).
Overall completeness and applicability of
evidence
The quality of the data concerning change in serum LDL choles-
terol and adverse events was, according to GRADE, classified as
moderate. These data are applicable in the treatment of FH chil-
dren. In conclusion, statins lowered LDL cholesterol effectively
(advantage). Significant adverse events were not present during
the statin treatment (potential harm).
Quality of the evidence
Blinding (performance bias and detection bias) was not present
in any studies. Bias from random sequence generation (selection
bias) was not present in two studies and the data were not clearly
stated in seven studies. Bias from allocation concealment (selection
bias) and selective reporting (reporting bias) can not totally be
excluded, but it is very unlikely. In conclusion it can be stated that
all the studies appeared to be well run and we do not think any
abovementioned factorswill influence the results in a negativeway.
Quality of evidence varied from moderate (change in serum LDL
cholesterol and adverse events) to low (change in carotid intima-
media thickness, change in measures if growth and maturation,
liver dysfunction, myopathy and change in endothelial function).
Potential biases in the review process
A comprehensive literature search was carefully carried out and we
consider that most controlled studies were identified. Study proto-
cols varied between the included studies and data were presented
slightly differently between the studies. In conclusion we found
no potential bias in the review process.
Agreements and disagreements with other
studies or reviews
Our findings are similar to those reported in two systematic re-
views (Arambepola 2007; Avis 2007). In the Arabepola review, re-
sults of a parallel-group randomised placebo-controlled trial con-
cerning heterozygous FHchildrenwith LDL andHDLcholesterol
and triglycerides as outcomes were pooled using standard meta-
analytical methods (Arambepola 2007). In the Avis review, they
performed a meta-analysis of randomized, double-blind, placebo-
controlled trials evaluating statin therapy in children aged 8 to 18
years with heterozygous FH and six studies (n = 798 children)
with 12 to 104 weeks of treatment were included (Avis 2010).
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A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Statin treatment is an effective lipid-lowering therapy in children
with heterozygous FH.No safety issues were identified in the short
term up to two years. Since statin treatment in children with FH
is not acutely or sub-acutely a life-saving treatment, it would be
difficult to accept any clinically significant adverse events in this
patient group. This treatment should be combined with regular
pediatric follow-up and parents informed about potential side-
effects and interaction with concomitant medication.
Implications for research
Much larger and longer-term randomized clinical trials are needed
to ensure that statins are a safe therapy in the long term in children.
Growth, neurological development, cognitive function andquality
of life should be assessed during follow-up.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Avis 2010
Methods * Design: RCT
* Randomization stratified by center
* Blinding: double
* Concealment of allocation: nr
* Setting: 20 centers
* Country: Netherlands, Canada, Norway, USA
* Follow-up: 12 weeks
Participants Individuals with HeFH (N = 177)
* Diagnosis: documented genetic effect or LDL-C
>
= 190 mg/dL or LDL-C > 160 mg/
dL and early CVD in family
* Inclusion: age 10 - 17 years, HeFH, Tanner stage
>
= II, females at least 1 year post-
menarche
* Exclusion: nr
* Base population: nr
Age: 10 - 17 years
Male: 55%
Race: White populations 94%
Height (mean): 164 cm
Weight (mean): 58 kg
BMI (mean): nr
LDL-C (mean):? mmol/L (233 mg/dL)
Interventions * Treatment: rosuvastatin in 3 treatment arms (n = 130), 5 mg daily (n = 42), 10 mg
daily (n = 44) and 20 mg daily (n = 45)
* Control: placebo (n = 46)
* Run-in: diet only for 6 weeks
* Diet: nr
Outcomes LDL-C: Friedewald’s formula
TC
HDLC
TG
ASAT
ALAT
CK
Myopathy: myalgia
Adverse events: adverse event
Notes * Open-label phase for 40 weeks after the RCT, data not used in this review
Risk of bias
Bias Authors’ judgement Support for judgement
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Avis 2010 (Continued)
Random sequence generation (selection
bias)
Unclear risk Described as stratified but randomization
procedure not described
Allocation concealment (selection bias) Unclear risk nr
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Compliance: 87%
Dropout: 2%
Losses to follow-up: 1%
Missing from analysis: 1%
Selective reporting (reporting bias) Unclear risk No indication to suspect selective report-
ing.
Braaskamp 2015a
Methods * Design: RCT
* Randomization stratified by age and baseline LDL-C
* Blinding: double
* Concealment of allocation: nr
* Setting: 10 centers
* Country: Netherlands, Greece, Norway, Italy, Spain, France
* Follow-up: 12 weeks
Participants Individuals with HeFH (N = 103)
* Diagnosis: documented genetic effect or LDL-C
>
= 160 mg/dL or LDL-C > 130 mg/
dL and male, early CVD in family, HDL-C < 45 mg/dL, TG > 150 mg/dL, lipoprotein
(a) > 75 nmol/L, type 2 diabetes mellitus diagnosed and blood pressure > 95th percentile
for age and height.
* Inclusion: age 6 - 17 years, HeFH
* Exclusion: nr
* Base population: nr
Age: 6 - 17 years
Male: 45%
Height (mean): 148 cm
Weight (mean): 44 kg
BMI (mean): 19.1 kg/m²
LDL-C (mean): 232 mg/dL
Interventions * Treatment: pitavastatin in 3 treatment arms (n = 76), 1 mg daily (n = 26), 2 mg daily
(n = 26) and 4 mg daily (n = 24)
* Control: placebo (n = 27)
* Run-in: diet only for 5 weeks
* Diet: nr
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Braaskamp 2015a (Continued)
Outcomes LDL-C (SD for mean percentage change not reported)
TC (SD for mean percentage change not reported)
HDL-C (SD for mean percentage change not reported)
TG (SD for mean percentage change not reported)
ASAT
ALAT
CK
Myopathy: myalgia
Adverse events: (adverse event not reported separately for the treatment groups)
Notes No indication to suspect selective reporting.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk nr; multicenter study, central randomiza-
tion assumed.
Allocation concealment (selection bias) Unclear risk nr
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Compliance: nr
Dropout: 3%
Losses to follow-up: 0%
Missing from analysis: 0%
Selective reporting (reporting bias) Unclear risk No indication to suspect selective report-
ing.
Clauss 2005
Methods * Design: RCT
* Randomization process: nr
* Blinding: double
* Concealment of allocation: by randomised numbers
* Setting: 12 medical centers
* Country: USA
* Follow-up: 4 and 24 weeks
Participants * Participants with HeFH (N = 54)
* Diagnosis: 1 parent with FH, LDL-C > 4.1mmol/L
* Inclusion: age 10 - 17 years; female; LDL-C 4.1-10.3 mmol/L on diet; TG < 4.0 mmol/
L; postmenarchal > 1 year
* Exclusion: pregnancy; under/overweight; HoFH; dyslipidemia I, III-V; DM, hypothy-
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Clauss 2005 (Continued)
roidism; renal disorder; certain medication (immunosuppressants, corticosteroids, cy-
tochrome P-450 inhibitors)
* Base population: unclear; 81 individuals were screened
* Age: 11 - 18 years
* Male: 0%
* Race: nr
* Height (mean): 164 cm
* Weight (mean): 60 kg
* BMI (mean): 23 kg/m²
* LDL-C (mean): 5.5 mmol/L
Interventions * Intervention: lovastatin 40 mg daily; started with 20 mg for 4 weeks, then increased to
40 mg (n = 35)
* Control: placebo (n = 19)
* Drugs discontinued 6 - 8 weeks before randomisation; diet/placebo run-in for 4 weeks
* AHA step 1 diet or similar instruction at baseline
Outcomes LDL-C: enzymatic method, calculated Friedewald’s formula
TC: enzymatic method
HDL-C: heparin-manganese chloride method
TG: enzymatic method
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomization process by randomised
numbers.
Allocation concealment (selection bias) Unclear risk nr
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Compliance: nr
Dropout: 6%
Losses to follow-up: 6%
Missing from analysis: 0%
Selective reporting (reporting bias) Unclear risk No indication to suspect selective report-
ing.
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Couture 1998
Methods * Design: RCT
* Randomization process: nr
* Blinding: double
* Concealment of allocation: nr
* Setting: 1 research clinic
* Country: Canada
* Follow-up: 6 weeks
Participants * Individuals with HeFH (N = 63)
* Diagnosis: unclear, LDL-C > 95th percentile on diet
* Inclusion: age < 18 years; HeFH; LDL-C > 95th percentile on diet;
* Exclusion: DM; anorexia; kidney, liver or thyroid disorder; delayed puberty
* Base population: all potential participants screened
* Age 8 - 17 years
* Male 59%
* Race: nr
* Height (mean) 153 cm
* weight (mean) 46 kg
* BMI (mean) nr
* LDL-C (mean) 5.8 mmol/L
Interventions * Treatment: simvastatin 20 mg daily (n = 47)
* Control: placebo (n = 16)
* Run-in: placebo 4 weeks
* Diet: AHA phase I, dietary counselling throughout the trial
Outcomes LDL-C: enzymatic method, calculated Friedewald’s formula
TC: enzymatic method
HDL-C: heparin-manganese chloride method
TG: enzymatic method
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomized, process not re-
ported.
Allocation concealment (selection bias) Unclear risk nr
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Compliance: nr
Dropout: nr
Losses to follow-up: 0%
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Couture 1998 (Continued)
Missing from analysis: 0%
Selective reporting (reporting bias) Unclear risk No indication to suspect selective report-
ing.
de Jongh 2002a
Methods * Design: RCT
* Randomization process: nr
* Blinding: double
* Concealment of allocation: nr
* Setting: 7 countries, 9 medical centers
* Country: Canada, Costa Rica, France, Netherlands, New Zealand, Norway
* Follow-up: 24 and 48 weeks
Participants Individuals with HeFH (N = 175)
* Diagnosis: 1 parent clinical FH, LDL-C > 4.1mmol/L
* Inclusion: age
<
= 18 years; HeFH; LDL-C > 95th percentile; genetic diagnosis or family
history of high LDL-C
* Exclusion: smoking; vasoactive medication; serious illness; HT; DM
* Base population: nr
* Age: 10 - 17 years
* Male 57%
* Race: nr
* Height (mean): nr
*Weight (mean): nr
* BMI (mean): 22 kg/m²
* LDL-C (mean): 5.4 mmol/L
Interventions * Treatment: simvastatin 40 mg daily (n = 101); started with 10 mg, doubled at every 8
weeks up to 40 mg
* Control: placebo (n = 64)
* Run-in: diet + placebo for 4 weeks
* Diet: nr
Outcomes LDL-C: enzymatic method
TC: enzymatic method
HDL-C: enzymatic method
TG: enzymatic method
FMD: on brachial artery by ultrasonography, method described (on subset of Dutch
group)
CRP method: nr
ASAT method: nr
ALAT method: nr
CK method: nr
Puberty: Tanner staging by clinical examination
Myopathy: criteria nr
Adverse events: drug-related clinical adverse event, criteria unclear, method: nr
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de Jongh 2002a (Continued)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomized, process not re-
ported.
Allocation concealment (selection bias) Unclear risk nr
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Compliance: nr
Dropout: 6%
Losses to follow-up: 6%
Missing from analysis: 6%
Selective reporting (reporting bias) Unclear risk No indication to suspect selective report-
ing.
Knipscheer 1996
Methods * Design: RCT
* Randomization: stratified
* Blinding: double
* Concealment of allocation: nr
* Setting: no. of medical centers nr
* Country: Netherlands
* Follow-up: 12 weeks
Participants Individuals with HeFH (N = 72)
* Diagnosis: LDL-C > 95th percentile on diet and HC or early AS in family
* Inclusion: age 8 - 16 years; HeFH ~ LDL-C > 95th %tile on diet; HC or early AS in
family
* Exclusion: major surgery within 3 months; drugs interfering with lipid metabolism;
liver or renal dysfunction
* Base population: nr
Age: 8 - 16 years
Male: 35%
Race: 92%
Height (mean): nr
Weight (mean): 47 kg
BMI (mean): nr
LDL-C (mean): 6.5 mmol/L
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Knipscheer 1996 (Continued)
Interventions * Treatment: pravastatin in 3 treatment arms (n = 53), 5 mg daily (n = 17?), 10 mg daily
(n = 18?) and 20 mg daily (n = 18?)
* Control: placebo (n = 18)
* Run-in: diet + placebo for 8 weeks
* Diet: lipid-lowering diet, pre-study diet evaluated with 5 day dietary recall
Outcomes LDL-C: enzymatic method, Friedewald’s formula
TC: enzymatic method
HDL-C: enzymatic method
TG: enzymatic method
ASAT: routine biochemistry
ALAT: routine biochemistry
CK: routine biochemistry
Myopathy: myalgia, recorded by blinded physicians
Adverse events: adverse event, recorded by blinded physicians
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as stratified but randomization
procedure not described
Allocation concealment (selection bias) Unclear risk nr
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Compliance: unclear
Dropout: nr
Losses to follow-up: 1%
Missing from analysis: 1%
Selective reporting (reporting bias) Unclear risk No indication to suspect selective report-
ing.
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McCrindle 2003
Methods * Design: RCT
* Randomization process: nr
* Blinding: double
* Concealment of allocation: nr
* Setting: 20 medical centers (6 USA, 5 Canada, 8 Europe, 1 South Africa)
* Country: USA, Canada, Ireland, France, Spain, England, Sweden, Norway, South
Africa
* Follow-up: 26 weeks
Participants * Individuals with HeFH (N = 187)
* Diagnosis: FH or severe hypercholesterolemia and LDL-C > 4.9 mmol/L OR LDL-
C > 4.1 mmol/L and family history of FH OR LDL-C > 4.1 mmol/L and premature
CHD in 1°/2° relatives
* Inclusion: age 10 - 17 years; HeFH or LDL-C
>
= 4.9 mmol/L or LDL-C
>
= 4.1 mmol/
L with HC or early AS in family; Tanner
>
= II; LDL-C
>
= 4.1 mmol/L w/ diet during
baseline phase
* Exclusion: premenarche; pregnancy; under or overweight; liver or kidney disorder;
HoFH; other clinical trial; hypersensitivity to statins
* base population: nr
Age: 10 - 17 years
Male: 69%
Race: 92% white
Height (mean): nr
Weight (mean): nr
BMI (mean): nr
LDL-C (mean): 5.7 mmol/L
Interventions * Treatment: atorvastatin 10 - 20 mg daily (n = 140); median 20 mg, increased to 20 mg
if LDL-C
>
= 3.4 mmol/L at 4 weeks
* Control: placebo (n = 47)
* Run-in: washout for 4 weeks before the trial; placebo/diet run-in for 4 weeks
* Diet: NCEP step 1 diet; instructions in the beginning of the study
Outcomes LDL-C: samples analyzed centrally
TC: samples analyzed centrally
HDL-C: samples analyzed centrally
TG: samples analyzed centrally
ALAT: >3 x ULN samples analyzed in a routine manner
ASAT: >3 x ULN samples analyzed in a routine manner
Puberty: increase in Tanner staging
>
= 1, clinical examination
Adverse event: self-report or detected by the investigator
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
34Statins for children with familial hypercholesterolemia (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
McCrindle 2003 (Continued)
Random sequence generation (selection
bias)
Unclear risk Described as randomized, process not re-
ported.
Allocation concealment (selection bias) Unclear risk nr
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Compliance: nr
Dropout: 2%
Losses to follow-up: 0%
Missing from analysis: 0%
Selective reporting (reporting bias) Unclear risk No indication to suspect selective report-
ing.
Stein 1999
Methods * Design: RCT
* Randomization process: nr
* Blinding: double
* Concealment of allocation: nr
* Setting: 14 pediatric clinics (13 USA, 1 Finland)
* Country: USA, Finland
* Follow-up: 24 and 48 weeks
Participants * Participants with HeFH (N = 132)
* Diagnosis: LDL-C > 4.9mmol/L and 1 parent LDL-C > 4.9mmol/l; or LDL-C > 5.
7mmol/L and CAD death in 1 parent
* Inclusion: age 10 - 17 years; LDL-C 4.9 - 13.0 mmol/L on diet and
>
= 1 parent with
LDL-C
>
= 4.9 mmol/L with or LDL-C 5.7 - 13.0 mmol/L on diet and a parent died of
CAD; (Tanner > I required later by FDA > 8 participants needed to discontinue)
* Exclusion: delayed puberty; under/overweight;HoFH; secondary hyperlipidaemia; TG
disorders
* Base population: unclear
* Age: 11 - 17 years
* Male: 100%
* Race: 93%
* Height (mean): 159 cm
* Weight (mean): 52 kg
* BMI (mean): 21 kg/m²
* LDLC (mean): 6.5 mmol/L
Interventions * Treatment: lovastatin 40 mg in the evening (n = 63); started with 10 mg, increased to
20/40 mg at weeks 8/16
* Control: placebo (n = 59)
* Run-in: diet for 4 months; placebo run-in for 4 weeks
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Stein 1999 (Continued)
* Diet: AHA pediatric diet; instructed, monitored and evaluated throughout trial
Outcomes LDL-C: enzymatic method
TC: enzymatic method
HDL-C: heparin-manganese chloride method
TG: enzymatic method
ALAT > 3 x ULN: samples analyzed centrally
ASAT > 3 x ULN: samples analyzed centrally
CK > 10 x ULN: samples analyzed centrally
Myalgia criteria: nr
Adverse event: new or worsening clinical adverse event, not otherwise specified
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomized, process not re-
ported.
Allocation concealment (selection bias) Unclear risk nr
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Compliance: nr
Dropout: 8%
Losses to follow-up: 8%
Missing from analysis: 8%
Selective reporting (reporting bias) Unclear risk No indication to suspect selective report-
ing.
Wiegman 2004
Methods * Design: RCT
* Randomization computer-generated in blocks of 8
* Blinding: double
* Compliance monitored by tablet counting
* Concealment of allocation: nr
* Setting: 1 medical center
* Country: Netherlands
* Follow-up: 104 weeks
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Wiegman 2004 (Continued)
Participants * Participants with HeFH (N = 214)
* Diagnosis: molecular diagnosis in parent and LDL-C > 4.0 mmol/L
* Inclusion: age 10 - 17 years; female; 1 parent with FH and LDL-C 4.1-10.3 mmol/L
on diet; TG < 4.0 mmol/L; postmenarchal > 1 year
* Exclusion: pregnancy; under/overweight; HoFH; dyslipidaemia I, III-V; DM, hy-
pothyroidism; renal disorder; certain medication (immunosuppressants, corticosteroids,
cytochrome P-450 inhibitors)
* Base population: unclear; 81 participants were screened
* Age: 8 - 18 years
* Male: 47%
* Race: nr
* Height (mean): 157 cm
* Weight (mean): 49 kg
* BMI (mean): 20 kg/m²
* LDL-C (mean): 6.2 mmol/L
Interventions * Treatment: pravastatin 20 to 40 mg daily in the evening depending on age (n = 104)
* Control: placebo (n = 107)
* Run-in: fat-restricted diet
* Diet: fat-restricted diet; 7 d dietary records; evaluated
Outcomes LDL-C: enzymatic method, calculated Friedewald’s formula
TC: enzymatic method
HDL-C: naheparin-manganese chloride method
TG: enzymatic method
ALAT: > 3 x ULN, analysis method: nr
ASAT: > 3 x ULN, analysis method: nr
CPK: > 4 x ULN, analysis method: nr
IMT: ultrasonography; method described
Puberty: Tanner staging, clinical examination
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated in blocks of 8.
Allocation concealment (selection bias) Unclear risk nr
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Compliance: unclear
Dropout: 5%
Losses to follow-up: 1%
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Wiegman 2004 (Continued)
Missing from analysis: 1%
Selective reporting (reporting bias) Unclear risk No indication to suspect selective report-
ing.
AHA: American Heart Association
ALAT: alanine amino transferase
ASAT: aspartate amino transferase
BMI: body mass index
CAD: coronary artery disease
CK: creatine kinase
CRP: C-reactive protein
CVD: cardiovascular disease
DM: diabetes mellitus
FH: familial hypercholesterolemia
FMD: flow-mediated dilatation
HC: hypercholesterolemia
HDL-C: high-density lipoprotein cholesterol
HeFH: heterozygous familial hypercholesterolemia
HoFH: homozygous familial hypercholesterolemia
HT: hypertension
IMT: intima-media thickness
LDL-C: low-density lipoprotein cholesterol
NCEP: National Cholesterol Education Panel
nr: not reported
RCT: randomized controlled trial
TC: total cholesterol
TG: triglycerides
ULN: upper limit of normal
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Athyros 2002 Publication type letter, no control group, not enough information reported
Braaskamp 2015b Cohort study.
Braaskamp 2015c Clinical trial without randomization.
Carreau 2011 Cohort study.
Chan 2016 No control group without medication.
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(Continued)
Dirisamer 2003 Clinical trial, no control group.
Gandelman 2011 Clinical trial, no control group, open-label.
Hedman 2003 Clinical trial, no control group.
Hedman 2005 Clinical trial, no control group.
Lambert 1996 Clinical trial, no control group.
Langslet 2016 Clinical trial, no placebo control group
McCrindle 2002 Randomised cross-over trial, comparison unacceptable (i.e. combination of 2 active drugs): one intervention
was 10 mg pravastatin plus 5 g colestipol and the other 10 g colestipol
Raal 1997 Clinical trial, no control group.
Sinzinger 2004 Cohort study.
Stefanutti 1999 Clinical trial, control diet alone, controls were not clearly defined, e.g. the diagnostic criteria for heterozygous
FH not reported, only age of the participants given
Stein 1989 Cohort study.
Stein 2016 Participants had homozygous FH.
Tada 2016 No control group without medication.
Teramoto 2016 PCSK 9 inhibitor used as add-on therapy and also not only people with FH included
van der Graaf 2006 Clinical trial, no control group.
FH: familial hypercholesterolemia
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D A T A A N D A N A L Y S E S
Comparison 1. Statins versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in carotid intima-media
thickness (mm)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 At 2 years 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Change in serum LDL
cholesterol level (%)
6 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 At 1 month 3 228 Mean Difference (IV, Fixed, 95% CI) -24.59 [-30.11, -19.
08]
2.2 At 6 months 4 528 Mean Difference (IV, Fixed, 95% CI) -34.97 [-37.51, -32.
44]
2.3 At 1 year 2 254 Mean Difference (IV, Fixed, 95% CI) -26.94 [-31.64, -22.
23]
2.4 At end of follow-up 6 669 Mean Difference (IV, Fixed, 95% CI) -32.15 [-34.90, -29.
40]
3 Change in puberty (Tanner stage
>
= 1 level)
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 At 6 months 2 355 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.66, 1.50]
3.2 At 1 year 1 139 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.51, 1.54]
3.3 At 2 years 1 211 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.77, 1.18]
4 Change in aspartate
aminotransferase levels (> 3x
ULN)
7 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 At 1 month 2 175 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 At 6 months 4 538 Risk Ratio (M-H, Fixed, 95% CI) 2.40 [0.29, 19.85]
4.3 At 1 year 2 254 Risk Ratio (M-H, Fixed, 95% CI) 2.03 [0.08, 49.09]
4.4 At 2 years 1 211 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.01, 4.23]
5 Change in alanine
aminotransferase levels (> 3x
ULN)
7 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 At 1 month 2 175 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 At 6 months 4 538 Risk Ratio (M-H, Fixed, 95% CI) 2.03 [0.24, 16.95]
5.3 At 1 year 2 254 Risk Ratio (M-H, Fixed, 95% CI) 2.03 [0.08, 49.09]
5.4 At 2 years 1 211 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Myopathy: Change in creatine
kinase levels (> 10x ULN)
6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 At 1 month 3 330 Risk Ratio (M-H, Fixed, 95% CI) 3.23 [0.18, 58.84]
6.2 At 6 months 2 229 Risk Ratio (M-H, Fixed, 95% CI) 0.22 [0.01, 5.28]
6.3 At 1 year 2 254 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.04, 10.57]
7 Change in flow-mediated
dilatation of brachial artery (%)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.1 At 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Change in serum total
cholesterol levels (%)
6 Mean Difference (IV, Fixed, 95% CI) Subtotals only
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8.1 At 1 month 3 228 Mean Difference (IV, Fixed, 95% CI) -18.31 [-22.55, -14.
06]
8.2 At 6 months 4 528 Mean Difference (IV, Fixed, 95% CI) -24.28 [-26.09, -22.
47]
8.3 At 1 year 2 254 Mean Difference (IV, Fixed, 95% CI) -27.60 [-30.64, -24.
57]
8.4 At the end of follow-up 6 669 Mean Difference (IV, Fixed, 95% CI) -26.53 [-28.54, -24.
51]
9 Change in serum HDL
cholesterol levels (%)
6 Mean Difference (IV, Fixed, 95% CI) Subtotals only
9.1 At 1 month 3 228 Mean Difference (IV, Fixed, 95% CI) 3.0 [-2.47, 8.47]
9.2 At 6 months 4 528 Mean Difference (IV, Fixed, 95% CI) 4.18 [1.54, 6.82]
9.3 At 1 year 2 254 Mean Difference (IV, Fixed, 95% CI) 2.56 [-1.17, 6.29]
9.4 At the end of follow-up 6 669 Mean Difference (IV, Fixed, 95% CI) 3.11 [0.55, 5.67]
10 Change in serum triglyceride
levels (%)
5 Mean Difference (IV, Fixed, 95% CI) Subtotals only
10.1 At 1 month 3 228 Mean Difference (IV, Fixed, 95% CI) 10.31 [-5.11, 25.74]
10.2 At 6 months 3 363 Mean Difference (IV, Fixed, 95% CI) -9.34 [-18.90, 0.22]
10.3 At 1 year 1 110 Mean Difference (IV, Fixed, 95% CI) 0.0 [-18.09, 18.09]
10.4 At the end of follow-up 5 525 Mean Difference (IV, Fixed, 95% CI) -3.27 [-12.03, 5.50]
11 Adverse events 6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
11.1 At 1 month 2 248 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.65, 1.13]
11.2 At 6 months 3 416 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.82, 1.27]
11.3 At 1 year 2 276 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.81, 1.26]
Analysis 1.1. Comparison 1 Statins versus control, Outcome 1 Change in carotid intima-media thickness
(mm).
Review: Statins for children with familial hypercholesterolemia
Comparison: 1 Statins versus control
Outcome: 1 Change in carotid intima-media thickness (mm)
Study or subgroup Statins Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 2 years
Wiegman 2004 104 -0.01 (0.048) 107 0.01 (0.044) -0.02 [ -0.03, 0.00 ]
-0.1 -0.05 0 0.05 0.1
Favours statins Favours placebo
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Analysis 1.2. Comparison 1 Statins versus control, Outcome 2 Change in serum LDL cholesterol level (%).
Review: Statins for children with familial hypercholesterolemia
Comparison: 1 Statins versus control
Outcome: 2 Change in serum LDL cholesterol level (%)
Study or subgroup Statins Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 1 month
Braaskamp 2015a 76 -31 (0) 27 1 (0) Not estimable
Clauss 2005 35 -23 (20) 19 3 (17) 29.7 % -26.00 [ -36.12, -15.88 ]
Knipscheer 1996 53 -27 (10) 18 -3 (13) 70.3 % -24.00 [ -30.58, -17.42 ]
Subtotal (95% CI) 164 64 100.0 % -24.59 [ -30.11, -19.08 ]
Heterogeneity: Chi2 = 0.11, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 8.74 (P < 0.00001)
2 At 6 months
Clauss 2005 35 -27 (20) 19 5 (17) 6.3 % -32.00 [ -42.12, -21.88 ]
de Jongh 2002a 101 -38 (16) 64 -1 (11) 37.7 % -37.00 [ -41.12, -32.88 ]
McCrindle 2003 140 -40 (13) 47 0 (13) 34.8 % -40.00 [ -44.30, -35.70 ]
Stein 1999 63 -27 (16) 59 -3 (15) 21.2 % -24.00 [ -29.50, -18.50 ]
Subtotal (95% CI) 339 189 100.0 % -34.97 [ -37.51, -32.44 ]
Heterogeneity: Chi2 = 21.81, df = 3 (P = 0.00007); I2 =86%
Test for overall effect: Z = 27.06 (P < 0.00001)
3 At 1 year
de Jongh 2002a 86 -41 (39) 58 0 (10) 29.7 % -41.00 [ -49.64, -32.36 ]
Stein 1999 61 -25 (16) 49 -4 (14) 70.3 % -21.00 [ -26.61, -15.39 ]
Subtotal (95% CI) 147 107 100.0 % -26.94 [ -31.64, -22.23 ]
Heterogeneity: Chi2 = 14.49, df = 1 (P = 0.00014); I2 =93%
Test for overall effect: Z = 11.22 (P < 0.00001)
4 At end of follow-up
Braaskamp 2015a 76 -31 (0) 27 1 (0) Not estimable
Clauss 2005 35 -27 (20) 19 5 (17) 7.4 % -32.00 [ -42.12, -21.88 ]
de Jongh 2002a 86 -41 (39) 58 0 (10) 10.1 % -41.00 [ -49.64, -32.36 ]
Knipscheer 1996 53 -27 (10) 18 -3 (13) 17.5 % -24.00 [ -30.58, -17.42 ]
McCrindle 2003 140 -40 (13) 47 0 (13) 41.0 % -40.00 [ -44.30, -35.70 ]
Stein 1999 61 -25 (16) 49 -4 (14) 24.0 % -21.00 [ -26.61, -15.39 ]
Subtotal (95% CI) 451 218 100.0 % -32.15 [ -34.90, -29.40 ]
Heterogeneity: Chi2 = 37.92, df = 4 (P<0.00001); I2 =89%
Test for overall effect: Z = 22.92 (P < 0.00001)
-50 -25 0 25 50
Favours statins Favours placebo
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Analysis 1.3. Comparison 1 Statins versus control, Outcome 3 Change in puberty (Tanner stage
>
= 1 level).
Review: Statins for children with familial hypercholesterolemia
Comparison: 1 Statins versus control
Outcome: 3 Change in puberty (Tanner stage 1 level)
Study or subgroup Statins Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At 6 months
de Jongh 2002a 18/104 9/64 33.2 % 1.23 [ 0.59, 2.57 ]
McCrindle 2003 39/140 15/47 66.8 % 0.87 [ 0.53, 1.43 ]
Subtotal (95% CI) 244 111 100.0 % 0.99 [ 0.66, 1.50 ]
Total events: 57 (Statins), 24 (Placebo)
Heterogeneity: Chi2 = 0.58, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
2 At 1 year
de Jongh 2002a 21/83 16/56 100.0 % 0.89 [ 0.51, 1.54 ]
Subtotal (95% CI) 83 56 100.0 % 0.89 [ 0.51, 1.54 ]
Total events: 21 (Statins), 16 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
3 At 2 years
Wiegman 2004 63/104 68/107 100.0 % 0.95 [ 0.77, 1.18 ]
Subtotal (95% CI) 104 107 100.0 % 0.95 [ 0.77, 1.18 ]
Total events: 63 (Statins), 68 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
0.5 0.7 1 1.5 2
Favours statins Favours placebo
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Analysis 1.4. Comparison 1 Statins versus control, Outcome 4 Change in aspartate aminotransferase levels
(> 3x ULN).
Review: Statins for children with familial hypercholesterolemia
Comparison: 1 Statins versus control
Outcome: 4 Change in aspartate aminotransferase levels (> 3x ULN)
Study or subgroup Statins Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At 1 month
Braaskamp 2015a 0/76 0/27 Not estimable
Knipscheer 1996 0/54 0/18 Not estimable
Subtotal (95% CI) 130 45 Not estimable
Total events: 0 (Statins), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 At 6 months
Clauss 2005 0/35 0/19 Not estimable
de Jongh 2002a 2/106 0/69 44.8 % 3.27 [ 0.16, 67.12 ]
McCrindle 2003 2/140 0/47 55.2 % 1.70 [ 0.08, 34.83 ]
Stein 1999 0/63 0/59 Not estimable
Subtotal (95% CI) 344 194 100.0 % 2.40 [ 0.29, 19.85 ]
Total events: 4 (Statins), 0 (Placebo)
Heterogeneity: Chi2 = 0.09, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.81 (P = 0.42)
3 At 1 year
de Jongh 2002a 1/86 0/58 100.0 % 2.03 [ 0.08, 49.09 ]
Stein 1999 0/61 0/49 Not estimable
Subtotal (95% CI) 147 107 100.0 % 2.03 [ 0.08, 49.09 ]
Total events: 1 (Statins), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
4 At 2 years
Wiegman 2004 0/104 2/107 100.0 % 0.21 [ 0.01, 4.23 ]
Subtotal (95% CI) 104 107 100.0 % 0.21 [ 0.01, 4.23 ]
Total events: 0 (Statins), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
0.001 0.01 0.1 1 10 100 1000
Favours statins Favours placebo
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Analysis 1.5. Comparison 1 Statins versus control, Outcome 5 Change in alanine aminotransferase levels (>
3x ULN).
Review: Statins for children with familial hypercholesterolemia
Comparison: 1 Statins versus control
Outcome: 5 Change in alanine aminotransferase levels (> 3x ULN)
Study or subgroup Statins Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At 1 month
Braaskamp 2015a 0/76 0/27 Not estimable
Knipscheer 1996 0/54 0/18 Not estimable
Subtotal (95% CI) 130 45 Not estimable
Total events: 0 (Statins), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 At 6 months
Clauss 2005 0/35 0/19 Not estimable
de Jongh 2002a 2/106 0/69 44.8 % 3.27 [ 0.16, 67.12 ]
McCrindle 2003 1/140 0/47 55.2 % 1.02 [ 0.04, 24.65 ]
Stein 1999 0/63 0/59 Not estimable
Subtotal (95% CI) 344 194 100.0 % 2.03 [ 0.24, 16.95 ]
Total events: 3 (Statins), 0 (Placebo)
Heterogeneity: Chi2 = 0.27, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.65 (P = 0.51)
3 At 1 year
de Jongh 2002a 1/86 0/58 100.0 % 2.03 [ 0.08, 49.09 ]
Stein 1999 0/61 0/49 Not estimable
Subtotal (95% CI) 147 107 100.0 % 2.03 [ 0.08, 49.09 ]
Total events: 1 (Statins), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
4 At 2 years
Wiegman 2004 0/104 0/107 Not estimable
Subtotal (95% CI) 104 107 Not estimable
Total events: 0 (Statins), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
0.002 0.1 1 10 500
Favours statins Favours placebo
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Analysis 1.6. Comparison 1 Statins versus control, Outcome 6 Myopathy: Change in creatine kinase levels
(> 10x ULN).
Review: Statins for children with familial hypercholesterolemia
Comparison: 1 Statins versus control
Outcome: 6 Myopathy: Change in creatine kinase levels (> 10x ULN)
Study or subgroup Statins Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At 1 month
Avis 2010 4/130 0/46 100.0 % 3.23 [ 0.18, 58.84 ]
Braaskamp 2015a 0/76 0/27 Not estimable
Knipscheer 1996 0/37 0/14 Not estimable
Subtotal (95% CI) 243 87 100.0 % 3.23 [ 0.18, 58.84 ]
Total events: 4 (Statins), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
2 At 6 months
Clauss 2005 0/35 0/19 Not estimable
de Jongh 2002a 0/106 1/69 100.0 % 0.22 [ 0.01, 5.28 ]
Subtotal (95% CI) 141 88 100.0 % 0.22 [ 0.01, 5.28 ]
Total events: 0 (Statins), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.94 (P = 0.35)
3 At 1 year
de Jongh 2002a 1/86 1/58 100.0 % 0.67 [ 0.04, 10.57 ]
Stein 1999 0/61 0/49 Not estimable
Subtotal (95% CI) 147 107 100.0 % 0.67 [ 0.04, 10.57 ]
Total events: 1 (Statins), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
0.01 0.1 1 10 100
Favours statins Favours placebo
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Analysis 1.7. Comparison 1 Statins versus control, Outcome 7 Change in flow-mediated dilatation of
brachial artery (%).
Review: Statins for children with familial hypercholesterolemia
Comparison: 1 Statins versus control
Outcome: 7 Change in flow-mediated dilatation of brachial artery (%)
Study or subgroup Statins Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 6 months
de Jongh 2002a 28 3.9 (4.3) 22 1.2 (3.9) 2.70 [ 0.42, 4.98 ]
-4 -2 0 2 4
Favours placebo Favours statins
Analysis 1.8. Comparison 1 Statins versus control, Outcome 8 Change in serum total cholesterol levels (%).
Review: Statins for children with familial hypercholesterolemia
Comparison: 1 Statins versus control
Outcome: 8 Change in serum total cholesterol levels (%)
Study or subgroup Statins Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 1 month
Braaskamp 2015a 76 -25 (0) 27 1 (0) Not estimable
Clauss 2005 35 -17 (15) 19 2 (13) 30.6 % -19.00 [ -26.67, -11.33 ]
Knipscheer 1996 53 -20 (8) 18 -2 (10) 69.4 % -18.00 [ -23.10, -12.90 ]
Subtotal (95% CI) 164 64 100.0 % -18.31 [ -22.55, -14.06 ]
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 8.45 (P < 0.00001)
2 At 6 months
Clauss 2005 35 -22 (15) 19 5 (13) 5.6 % -27.00 [ -34.67, -19.33 ]
de Jongh 2002a 101 -28 (13) 64 -1 (10) 26.5 % -27.00 [ -30.53, -23.47 ]
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(. . . Continued)
Study or subgroup Statins Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
McCrindle 2003 140 -31 (12) 47 -2 (10) 27.1 % -29.00 [ -32.48, -25.52 ]
Stein 1999 63 -21 (8) 59 -2 (8) 40.8 % -19.00 [ -21.84, -16.16 ]
Subtotal (95% CI) 339 189 100.0 % -24.28 [ -26.09, -22.47 ]
Heterogeneity: Chi2 = 23.10, df = 3 (P = 0.00004); I2 =87%
Test for overall effect: Z = 26.23 (P < 0.00001)
3 At 1 year
de Jongh 2002a 86 -31 (12) 58 1 (10) 70.7 % -32.00 [ -35.61, -28.39 ]
Stein 1999 61 -20 (16) 49 -3 (14) 29.3 % -17.00 [ -22.61, -11.39 ]
Subtotal (95% CI) 147 107 100.0 % -27.60 [ -30.64, -24.57 ]
Heterogeneity: Chi2 = 19.40, df = 1 (P = 0.00001); I2 =95%
Test for overall effect: Z = 17.81 (P < 0.00001)
4 At the end of follow-up
Braaskamp 2015a 76 -25 (0) 27 1 (0) Not estimable
Clauss 2005 35 -22 (15) 19 5 (13) 6.9 % -27.00 [ -34.67, -19.33 ]
de Jongh 2002a 86 -31 (12) 58 1 (10) 31.1 % -32.00 [ -35.61, -28.39 ]
Knipscheer 1996 53 -20 (8) 18 -2 (10) 15.6 % -18.00 [ -23.10, -12.90 ]
McCrindle 2003 140 -31 (12) 47 -2 (10) 33.5 % -29.00 [ -32.48, -25.52 ]
Stein 1999 61 -20 (16) 49 -3 (14) 12.9 % -17.00 [ -22.61, -11.39 ]
Subtotal (95% CI) 451 218 100.0 % -26.53 [ -28.54, -24.51 ]
Heterogeneity: Chi2 = 32.59, df = 4 (P<0.00001); I2 =88%
Test for overall effect: Z = 25.81 (P < 0.00001)
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Analysis 1.9. Comparison 1 Statins versus control, Outcome 9 Change in serum HDL cholesterol levels (%).
Review: Statins for children with familial hypercholesterolemia
Comparison: 1 Statins versus control
Outcome: 9 Change in serum HDL cholesterol levels (%)
Study or subgroup Statins Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 1 month
Braaskamp 2015a 76 -1 (0) 27 1 (0) Not estimable
Clauss 2005 35 5 (14) 19 2 (12) 59.1 % 3.00 [ -4.12, 10.12 ]
Knipscheer 1996 53 7 (16) 18 4 (16) 40.9 % 3.00 [ -5.56, 11.56 ]
Subtotal (95% CI) 164 64 100.0 % 3.00 [ -2.47, 8.47 ]
Heterogeneity: Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.07 (P = 0.28)
2 At 6 months
Clauss 2005 35 3 (15) 19 3 (13) 11.8 % 0.0 [ -7.67, 7.67 ]
de Jongh 2002a 101 5 (14) 64 0 (16) 30.5 % 5.00 [ 0.22, 9.78 ]
McCrindle 2003 140 3 (15) 47 -2 (13) 34.8 % 5.00 [ 0.53, 9.47 ]
Stein 1999 63 5 (16) 59 1 (15) 23.0 % 4.00 [ -1.50, 9.50 ]
Subtotal (95% CI) 339 189 100.0 % 4.18 [ 1.54, 6.82 ]
Heterogeneity: Chi2 = 1.39, df = 3 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 3.11 (P = 0.0019)
3 At 1 year
de Jongh 2002a 86 3 (15) 58 0 (15) 55.8 % 3.00 [ -2.00, 8.00 ]
Stein 1999 61 1 (16) 49 -1 (14) 44.2 % 2.00 [ -3.61, 7.61 ]
Subtotal (95% CI) 147 107 100.0 % 2.56 [ -1.17, 6.29 ]
Heterogeneity: Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 1.34 (P = 0.18)
4 At the end of follow-up
Braaskamp 2015a 76 -1 (0) 27 1 (0) Not estimable
Clauss 2005 35 3 (15) 19 3 (13) 11.1 % 0.0 [ -7.67, 7.67 ]
de Jongh 2002a 86 3 (15) 58 0 (15) 26.3 % 3.00 [ -2.00, 8.00 ]
Knipscheer 1996 53 7 (16) 18 4 (16) 9.0 % 3.00 [ -5.56, 11.56 ]
McCrindle 2003 140 3 (15) 47 -2 (13) 32.8 % 5.00 [ 0.53, 9.47 ]
Stein 1999 61 1 (16) 49 -1 (14) 20.8 % 2.00 [ -3.61, 7.61 ]
Subtotal (95% CI) 451 218 100.0 % 3.11 [ 0.55, 5.67 ]
Heterogeneity: Chi2 = 1.47, df = 4 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 2.38 (P = 0.017)
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Analysis 1.10. Comparison 1 Statins versus control, Outcome 10 Change in serum triglyceride levels (%).
Review: Statins for children with familial hypercholesterolemia
Comparison: 1 Statins versus control
Outcome: 10 Change in serum triglyceride levels (%)
Study or subgroup Statins Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 1 month
Braaskamp 2015a 76 -5 (0) 27 2 (0) Not estimable
Clauss 2005 35 -10 (36) 19 -11 (49) 37.9 % 1.00 [ -24.05, 26.05 ]
Knipscheer 1996 53 4 (41) 18 -12 (35) 62.1 % 16.00 [ -3.58, 35.58 ]
Subtotal (95% CI) 164 64 100.0 % 10.31 [ -5.11, 25.74 ]
Heterogeneity: Chi2 = 0.85, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 1.31 (P = 0.19)
2 At 6 months
Clauss 2005 35 -7 (40) 19 0 (42) 17.2 % -7.00 [ -30.07, 16.07 ]
McCrindle 2003 140 -12 (34) 47 1 (43) 50.0 % -13.00 [ -26.52, 0.52 ]
Stein 1999 63 6 (48) 59 11 (46) 32.8 % -5.00 [ -21.68, 11.68 ]
Subtotal (95% CI) 238 125 100.0 % -9.34 [ -18.90, 0.22 ]
Heterogeneity: Chi2 = 0.58, df = 2 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 1.92 (P = 0.055)
3 At 1 year
Stein 1999 61 6 (47) 49 6 (49) 100.0 % 0.0 [ -18.09, 18.09 ]
Subtotal (95% CI) 61 49 100.0 % 0.0 [ -18.09, 18.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
4 At the end of follow-up
Braaskamp 2015a 76 -5 (0) 27 2 (0) Not estimable
Clauss 2005 35 -7 (40) 19 0 (42) 14.4 % -7.00 [ -30.07, 16.07 ]
Knipscheer 1996 53 4 (41) 18 -12 (35) 20.1 % 16.00 [ -3.58, 35.58 ]
McCrindle 2003 140 -12 (34) 47 1 (43) 42.0 % -13.00 [ -26.52, 0.52 ]
Stein 1999 61 6 (47) 49 6 (49) 23.5 % 0.0 [ -18.09, 18.09 ]
Subtotal (95% CI) 365 160 100.0 % -3.27 [ -12.03, 5.50 ]
Heterogeneity: Chi2 = 5.94, df = 3 (P = 0.11); I2 =49%
Test for overall effect: Z = 0.73 (P = 0.47)
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Analysis 1.11. Comparison 1 Statins versus control, Outcome 11 Adverse events.
Review: Statins for children with familial hypercholesterolemia
Comparison: 1 Statins versus control
Outcome: 11 Adverse events
Study or subgroup Statins Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At 1 month
Avis 2010 73/130 25/46 73.2 % 1.03 [ 0.76, 1.40 ]
Knipscheer 1996 10/54 9/18 26.8 % 0.37 [ 0.18, 0.77 ]
Subtotal (95% CI) 184 64 100.0 % 0.86 [ 0.65, 1.13 ]
Total events: 83 (Statins), 34 (Placebo)
Heterogeneity: Chi2 = 6.58, df = 1 (P = 0.01); I2 =85%
Test for overall effect: Z = 1.10 (P = 0.27)
2 At 6 months
Clauss 2005 23/35 13/19 26.4 % 0.96 [ 0.65, 1.42 ]
de Jongh 2002a 6/106 3/69 5.7 % 1.30 [ 0.34, 5.03 ]
McCrindle 2003 88/140 29/47 67.9 % 1.02 [ 0.79, 1.32 ]
Subtotal (95% CI) 281 135 100.0 % 1.02 [ 0.82, 1.27 ]
Total events: 117 (Statins), 45 (Placebo)
Heterogeneity: Chi2 = 0.22, df = 2 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.17 (P = 0.86)
3 At 1 year
de Jongh 2002a 4/86 2/58 4.8 % 1.35 [ 0.26, 7.13 ]
Stein 1999 48/67 47/65 95.2 % 0.99 [ 0.80, 1.23 ]
Subtotal (95% CI) 153 123 100.0 % 1.01 [ 0.81, 1.26 ]
Total events: 52 (Statins), 49 (Placebo)
Heterogeneity: Chi2 = 0.14, df = 1 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.07 (P = 0.94)
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WH A T ’ S N E W
Last assessed as up-to-date: 28 June 2017.
Date Event Description
28 June 2017 New citation required but conclusions have not changed One new trial (107 participants) has been included in this
update of the review (Braaskamp 2015a). However, this
did not lead to any major changes in the conclusions of
the review
28 June 2017 New search has been performed One new trial has been included in this update of the
review (Braaskamp 2015a). However, this did not lead to
any major changes in the conclusions of the review
H I S T O R Y
Protocol first published: Issue 1, 2007
Review first published: Issue 7, 2010
Date Event Description
3 July 2014 New search has been performed One new trial has been included in the review update
(Avis 2010).
We are now using the definitions of statin-related my-
opathy provided by the U.S. Food and Drug Admin-
istration which relate to two clinical entities are used:
(1) myopathy (creatine kinase over 10 x ULN); and (2)
rhabdomyolysis (creatine kinase over 50 ULN and evi-
dence of organ damage) (Joy 2009).
One sub-study of the de Jongh 2002 study (de Jongh
2002b), previously listed as a separate included study,
has been correctly linked under the de Jongh 2002 in-
cluded study (de Jongh 2002a).
3 July 2014 New citation required but conclusions have not
changed
One new trial has been included in this update of the
review (Avis 2010). However, this did not lead to any
major changes in the conclusions of the review
20 October 2008 Amended Converted to new review format.
15 October 2007 New citation required and conclusions have changed Substantive amendment
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C O N T R I B U T I O N S O F A U T H O R S
Conceiving the review (AV02, PK01, SH01)
Designing the review (AV02, JK01, PK01, SH01)
Coordinating the review (AV02)
Data collection for the review (AV02, JK01)
Developing search strategy (JK01)
Undertaking searches (AV02, JK01)
Screening search results (AV02, JK01)
Organising retrieval of papers (AV02, JK01)
Screening retrieved papers against inclusion criteria (AV02, JK01)
Appraising quality of papers (AV02, JK01, PK01)
Abstracting data from papers (AV02, PK01)
Providing additional data about papers (JK01,SH01)
Data management for the review (JK01)
Entering data into RevMan (JK01)
Analysis of data (JK01)
Interpretation of data (AV02, JK01, TS01, PK01, SH01, AW, ST)
Providing a methodological perspective (JK01)
Providing a clinical perspective (AV02, G01, TS01, PK01, SH01, AW, ED,ST)
Providing a policy perspective (TS01, PK01, SH01)
Providing a consumer perspective
Writing the review (AV02, JK01, PK01)
Providing general advice on the review (TS01, PK01, SH01, AW, ST)
Securing funding for the review (AV02, JK01, PK01)
D E C L A R A T I O N S O F I N T E R E S T
Disclosure issues and time periods:
None of the review authors is either employed by a drug company or is a member of the board of a drug company.
Some of the review authors have previously:
- been a guest lecturer in meetings arranged by a drug company;
- participated in an international conference, the travel expenses and participation fee sponsored by a drug company;
- been a member of the national advisory board of a drug company;
- been a clinical investigator in a statin trial.
Note: Drug company here means a company selling statins.
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Finland.
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This systematic review was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We changed the age limit of participants from 17 years to 18 years. During the study selection, it became apparent several centres use
18 years as the cut off point for pediatric to adult services and we feel excluding these data would introduce a bigger bias to the review
than changing the inclusion criteria.
Definitions of statin-related myopathy is now following U.S. Food and Drug Administration definitions and only two clinical entities
are used: 1) myopathy (creatine kinase over 10 x upper limit of normal (ULN)) and rhabdomyolysis (creatine kinase over 50 ULN and
evidence of organ damage) (Joy 2009).
We grouped outcome data into those measured at at six months (± two weeks), at one year (± four weeks) and at two years.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Heterozygote; Alanine Transaminase [blood]; Aspartate Aminotransferases [blood]; Brachial Artery [drug effects]; Carotid Intima-
Media Thickness; Cholesterol, LDL [blood]; Creatine Kinase [blood]; Hydroxymethylglutaryl-CoA Reductase Inhibitors [adverse ef-
fects; ∗therapeutic use]; Hyperlipoproteinemia Type II [blood; ∗drug therapy; genetics]; Puberty [drug effects]; Randomized Controlled
Trials as Topic; Vasodilation [drug effects]
MeSH check words
Adolescent; Child; Child, Preschool; Female; Humans; Male
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